Fortive (FTV) 10-Q26 Oct 222022 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2022	Oct. 24, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	1-37654
Entity Registrant Name	Fortive Corporation
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-5654583
Entity Address, Address Line One	6920 Seaway Blvd
Entity Address, City or Town	Everett,
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98203
City Area Code	425
Local Phone Number	446-5000
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	FTV
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		353,808,253
Amendment flag	false
Document fiscal year focus	2022
Document fiscal period focus	Q3
Entity central index key	0001659166
Current fiscal year end date	--12-31

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and equivalents	$ 705.3	$ 819.3
Trade accounts receivable, net	901	930.2
Inventories:
Finished goods	228.5	215.4
Work in process	105.1	94
Raw materials	226.9	203.3
Inventories	560.5	512.7
Prepaid expenses and other current assets	281.1	252.7
Total current assets	2,447.9	2,514.9
Property, plant and equipment, net of accumulated depreciation of $740.6 and $679.0 at September 30, 2022 and December 31, 2021, respectively	405.2	395.5
Other assets	494.2	512.9
Goodwill	8,977.5	9,152
Other intangible assets, net	3,568.3	3,890.2
Total assets	15,893.1	16,465.5
Current liabilities:
Current portion of long-term debt	999.9	2,151.7
Trade accounts payable	572.6	557.9
Accrued expenses and other current liabilities	1,019.6	1,005.3
Total current liabilities	2,592.1	3,714.9
Other long-term liabilities	1,346.3	1,426.3
Long-term debt	2,559	1,807.3
Commitments and Contingencies
Equity:
Preferred stock: $0.01 par value, 15.0 million shares authorized and no shares issued or outstanding at September 30, 2022 and December 31, 2021	0	0
Common stock: $0.01 par value, 2.0 billion shares authorized; 361.4 and 360.4 million issued; 353.8 and 359.1 million outstanding at September 30, 2022 and December 31, 2021, respectively	3.6	3.6
Additional paid-in capital	3,677.4	3,670
Treasury shares, at cost	(376.1)	0
Retained earnings	6,539.6	6,023.6
Accumulated other comprehensive loss	(453.7)	(185)
Total Fortive stockholders’ equity	9,390.8	9,512.2
Noncontrolling interests	4.9	4.8
Total stockholders’ equity	9,395.7	9,517
Total liabilities and equity	$ 15,893.1	$ 16,465.5

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 740.6	$ 679
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	2,000,000,000	2,000,000,000
Common stock, shares issued (in shares)	361,400,000	360,400,000
Common stock, shares outstanding (in shares)	353,800,000	359,100,000

Consolidated Condensed Statemen

Consolidated Condensed Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Total sales	$ 1,456	$ 1,301	$ 4,295.8	$ 3,879.9
Total cost of sales	(610.6)	(555.3)	(1,824.9)	(1,666.8)
Gross profit	845.4	745.7	2,470.9	2,213.1
Operating costs:
Selling, general and administrative expenses	(491.3)	(455.6)	(1,456.8)	(1,340.1)
Research and development expenses	(101.1)	(87.8)	(300.3)	(261.8)
Russia exit and wind down costs	(1.1)	0	(17.3)	0
Operating profit	251.9	202.3	696.5	611.2
Non-operating income (expense), net:
Interest expense, net	(26.4)	(25.1)	(66.2)	(78)
Loss on extinguishment of debt	0	0	0	(104.9)
Gain on investment in Vontier Corporation	0	0	0	57
Gain on litigation resolution	0	0	0	26
Other non-operating expense, net	(8)	(1.6)	(13.8)	(9.5)
Earnings from continuing operations before income taxes	217.5	175.6	616.5	501.8
Income taxes	(27.6)	(23)	(88.5)	(55.5)
Net earnings from continuing operations	189.9	152.6	528	446.3
Earnings (loss) from discontinued operations, net of income taxes	0	(0.3)	0	(2.9)
Net earnings	189.9	152.3	528	443.4
Mandatory convertible preferred dividends	0	0	0	(34.5)
Net earnings attributable to common stockholders	$ 189.9	$ 152.3	$ 528	$ 408.9
Net earnings per common share from continuing operations:
Basic (in dollars per share)	$ 0.53	$ 0.42	$ 1.48	$ 1.19
Diluted (in dollars per share)	0.53	0.42	1.46	1.18
Net earnings (loss) per share from discontinued operations:
Basic (in dollars per share)	0	0	0	(0.01)
Diluted (in dollars per share)	0	0	0	(0.01)
Net earnings per share:
Basic (in dollars per share)	0.53	0.42	1.48	1.18
Diluted (in dollars per share)	$ 0.53	$ 0.42	$ 1.46	$ 1.17
Average common stock and common equivalent shares outstanding:
Basic (in shares)	355.2	358.9	357.3	345.6
Diluted (in shares)	357.9	362.2	362	348.8
Sales of products and software
Total sales	$ 1,227.7	$ 1,107.1	$ 3,609.8	$ 3,320.3
Total cost of sales	(494.4)	(448.3)	(1,467.8)	(1,356.6)
Sales of services
Total sales	228.3	193.9	686	559.6
Total cost of sales	$ (116.2)	$ (107)	$ (357.1)	$ (310.2)

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 189.9	$ 152.3	$ 528	$ 443.4
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments	(112.4)	(35.7)	(270.4)	(53.8)
Pension adjustments	0.8	0.9	1.7	2.8
Total other comprehensive income (loss), net of income taxes	(111.6)	(34.8)	(268.7)	(51)
Comprehensive income	$ 78.3	$ 117.5	$ 259.3	$ 392.4

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions	Total	Preferred Stock	Preferred Stock Cumulative Effect, Period of Adoption, Adjusted Balance	Common Stock	Common Stock Cumulative Effect, Period of Adoption, Adjusted Balance	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjusted Balance	Treasury Shares	Treasury Shares Cumulative Effect, Period of Adoption, Adjusted Balance	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings Cumulative Effect, Period of Adoption, Adjusted Balance	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Cumulative Effect, Period of Adoption, Adjusted Balance	Noncontrolling Interests	Noncontrolling Interests Cumulative Effect, Period of Adoption, Adjusted Balance
Beginning balance (in shares) at Dec. 31, 2020		1.4		339
Beginning balance at Dec. 31, 2020		$ 0		$ 3.4		$ 3,554.5			$ 0		$ 5,547.4			$ (141.1)		$ 8.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the period											110.2
Dividends to common shareholders	$ (23.7)										(23.7)
Mandatory convertible preferred stock cumulative dividends	(17.3)										(17.3)
Other comprehensive income (loss)														(33.7)
Common stock-based award activity (in shares)				(0.4)
Common stock-based award activity						34.1
Shares withheld for taxes (in shares)				(0.1)
Shares withheld for taxes						(13.2)
Early extinguishment of 0.875% convertible senior notes due 2022						(11.6)
Change in noncontrolling interest																(0.8)
Ending balance (in shares) at Apr. 02, 2021		1.4		338.5
Ending balance at Apr. 02, 2021		$ 0		$ 3.4		3,563.8			0		5,616.6			(174.8)		7.7
Beginning balance (in shares) at Dec. 31, 2020		1.4		339
Beginning balance at Dec. 31, 2020		$ 0		$ 3.4		3,554.5			0		5,547.4			(141.1)		8.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the period	443.4
Dividends to common shareholders	(72.6)
Mandatory convertible preferred stock cumulative dividends	(34.5)
Other comprehensive income (loss)	(51)
Ending balance (in shares) at Oct. 01, 2021		0		358.6
Ending balance at Oct. 01, 2021		$ 0		$ 3.6		3,624.3			0		5,883.7			(192.1)		4.8
Beginning balance (in shares) at Dec. 31, 2020		1.4		339
Beginning balance at Dec. 31, 2020		$ 0		$ 3.4		3,554.5			0		5,547.4			(141.1)		8.5
Ending balance (in shares) at Dec. 31, 2021		0	0	359.1	359.1
Ending balance at Dec. 31, 2021	$ 9,517	$ 0	$ 0	$ 3.6	$ 3.6	3,670	$ (65.7)	$ 3,604.3	0	$ 0	6,023.6	$ 62.8	$ 6,086.4	(185)	$ (185)	4.8	$ 4.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	Accounting Standards Update 2020-06 [Member]
Beginning balance (in shares) at Apr. 02, 2021		1.4		338.5
Beginning balance at Apr. 02, 2021		$ 0		$ 3.4		3,563.8			0		5,616.6			(174.8)		7.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the period											180.9
Dividends to common shareholders	$ (23.7)										(23.7)
Mandatory convertible preferred stock cumulative dividends	(17.2)										(17.2)
Other comprehensive income (loss)														17.5
Common stock-based award activity (in shares)				0.6
Common stock-based award activity						35.9
Shares withheld for taxes (in shares)				(0.1)
Shares withheld for taxes						(0.6)
Conversion of Mandatory convertible preferred stock to common stock (in shares)		(1.4)		19.4
Conversion of Mandatory convertible preferred stock to common stock				$ 0.2
Change in noncontrolling interest						3										(3)
Ending balance (in shares) at Jul. 02, 2021		0		358.4
Ending balance at Jul. 02, 2021		$ 0		$ 3.6		3,602.1			0		5,756.6			(157.3)		4.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the period	152.3										152.3
Dividends to common shareholders	(25.2)										(25.2)
Other comprehensive income (loss)	(34.8)													(34.8)
Common stock-based award activity (in shares)				0.2
Common stock-based award activity						27.6
Shares withheld for taxes						(1.6)
Change in noncontrolling interest						(3.8)										0.1
Ending balance (in shares) at Oct. 01, 2021		0		358.6
Ending balance at Oct. 01, 2021		$ 0		$ 3.6		3,624.3			0		5,883.7			(192.1)		4.8
Beginning balance (in shares) at Dec. 31, 2021		0	0	359.1	359.1
Beginning balance at Dec. 31, 2021	9,517	$ 0	$ 0	$ 3.6	$ 3.6	3,670	(65.7)	3,604.3	0	0	6,023.6	62.8	6,086.4	(185)	(185)	4.8	4.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the period											165.1
Dividends to common shareholders	(25.1)										(25.1)
Mandatory convertible preferred stock cumulative dividends	0
Other comprehensive income (loss)														(38.9)
Common stock-based award activity (in shares)				0.5
Common stock-based award activity						23.8
Common stock repurchases (in shares)				(1)
Common stock repurchases									(63.8)
Shares withheld for taxes (in shares)				(0.2)
Shares withheld for taxes						(9)
Change in noncontrolling interest																0.5
Ending balance (in shares) at Apr. 01, 2022		0		358.4
Ending balance at Apr. 01, 2022		$ 0		$ 3.6		3,619.1			(63.8)		6,226.4			(223.9)		5.3
Beginning balance (in shares) at Dec. 31, 2021		0	0	359.1	359.1
Beginning balance at Dec. 31, 2021	9,517	$ 0	$ 0	$ 3.6	$ 3.6	3,670	$ (65.7)	$ 3,604.3	0	$ 0	6,023.6	$ 62.8	$ 6,086.4	(185)	$ (185)	4.8	$ 4.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the period	528
Dividends to common shareholders	(74.8)
Mandatory convertible preferred stock cumulative dividends	0
Other comprehensive income (loss)	(268.7)
Ending balance (in shares) at Sep. 30, 2022		0		353.8
Ending balance at Sep. 30, 2022	9,395.7	$ 0		$ 3.6		3,677.4			(376.1)		6,539.6			(453.7)		4.9
Beginning balance (in shares) at Apr. 01, 2022		0		358.4
Beginning balance at Apr. 01, 2022		$ 0		$ 3.6		3,619.1			(63.8)		6,226.4			(223.9)		5.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the period											173
Dividends to common shareholders	(24.9)										(24.9)
Mandatory convertible preferred stock cumulative dividends	0
Other comprehensive income (loss)														(118.2)
Common stock-based award activity (in shares)				0.2
Common stock-based award activity						32.7
Common stock repurchases (in shares)				(3)
Common stock repurchases									(179.1)
Shares withheld for taxes						(0.6)
Change in noncontrolling interest																(0.2)
Ending balance (in shares) at Jul. 01, 2022		0		355.6
Ending balance at Jul. 01, 2022		$ 0		$ 3.6		3,651.2			(242.9)		6,374.5			(342.1)		5.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the period	189.9										189.9
Dividends to common shareholders	(24.8)										(24.8)
Mandatory convertible preferred stock cumulative dividends	0
Other comprehensive income (loss)	(111.6)													(111.6)
Common stock-based award activity (in shares)				0.2
Common stock-based award activity						28.3			0
Common stock repurchases (in shares)				(2)
Common stock repurchases									(133.2)
Shares withheld for taxes						(2.1)
Change in noncontrolling interest																(0.2)
Ending balance (in shares) at Sep. 30, 2022		0		353.8
Ending balance at Sep. 30, 2022	$ 9,395.7	$ 0		$ 3.6		$ 3,677.4			$ (376.1)		$ 6,539.6			$ (453.7)		$ 4.9

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Changes in Equity (Parenthetical)	Sep. 30, 2022	Jan. 01, 2022	Oct. 01, 2021	Apr. 02, 2021	Feb. 22, 2019
0.875% senior convertible notes due 2022 \| Convertible Debt
Interest rate, stated percentage	0.875%	0.875%	0.875%	0.875%	0.875%

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021
Cash flows from operating activities:
Net earnings from continuing operations	$ 528	$ 446.3
Noncash items:
Amortization	287.4	235.4
Depreciation	61.6	56.1
Stock-based compensation expense	67.9	55.2
Russia exit and wind down costs	9.2	0
Loss on extinguishment of debt	0	104.2
Gain on investment in Vontier Corporation	0	(57)
Gain on litigation resolution	0	(26)
Change in trade accounts receivable, net	(21.4)	(20.4)
Change in inventories	(73.2)	(46.1)
Change in trade accounts payable	46.6	14.8
Change in prepaid expenses and other assets	(55.4)	(61.5)
Change in accrued expenses and other liabilities	(11.7)	4.9
Total operating cash provided by continuing operations	839	705.9
Total operating cash used in discontinued operations	0	(19.4)
Net cash provided by operating activities	839	686.5
Cash flows from investing activities:
Cash paid for acquisitions, net of cash received	(15.2)	(1,156.7)
Payments for additions to property, plant and equipment	(59.7)	(28)
Proceeds from sale of business	6.6	0
All other investing activities	0	1.1
Net cash used in investing activities	(68.3)	(1,183.6)
Cash flows from financing activities:
Proceeds from borrowings (maturities greater than 90 days), net of issuance costs	396.9	0
Net proceeds from commercial paper borrowings	381.3	215
Payment of 0.875% convertible senior notes due 2022	(1,156.5)	0
Repurchase of common shares	(376.1)	0
Payment of common stock cash dividend to shareholders	(74.8)	(72.6)
Repayment of borrowings (maturities greater than 90 days)	0	(611.1)
Payment of mandatory convertible preferred stock cash dividend to shareholders	0	(34.5)
All other financing activities	(9.2)	18.1
Net cash used in financing activities	(838.4)	(485.1)
Effect of exchange rate changes on cash and equivalents	(46.3)	(4.2)
Net change in cash and equivalents	(114)	(986.4)
Beginning balance of cash and equivalents	819.3	1,824.8
Ending balance of cash and equivalents	$ 705.3	$ 838.4

Consolidated Condensed Statem_6

Consolidated Condensed Statements of Cash Flows (Parenthetical)	Sep. 30, 2022	Jan. 01, 2022	Oct. 01, 2021	Apr. 02, 2021	Feb. 22, 2019
0.875% senior convertible notes due 2022 \| Convertible Debt
Interest rate, stated percentage	0.875%	0.875%	0.875%	0.875%	0.875%

BUSINESS OVERVIEW

BUSINESS OVERVIEW	9 Months Ended
BUSINESS OVERVIEW	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS OVERVIEW	NOTE 1. BUSINESS OVERVIEW Fortive Corporation (“Fortive,” “the Company,” “we,” “us,” or “our”) is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Our strategic segments - Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions - include well-known brands with leading positions in their markets. Our businesses design, develop, manufacture, and service professional and engineered products, software, and services, building upon leading brand names, innovative technologies, and significant market positions. Our research and development, manufacturing, sales, distribution, service, and administrative facilities are located in more than 50 countries around the world. We prepared the unaudited consolidated condensed financial statements included herein in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) applicable for interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations; however, we believe the disclosures are adequate to make the information presented not misleading. The consolidated condensed financial statements included herein should be read in conjunction with the audited annual consolidated financial statements as of and for the year ended December 31, 2021 and the footnotes (“Notes”) thereto included within our 2021 Annual Report on Form 10-K. In our opinion, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to fairly present our financial position as of September 30, 2022 and December 31, 2021, our results of operations, comprehensive income, and stockholders’ equity for the three and nine month periods ended September 30, 2022 and October 1, 2021, and cash flows for the nine month periods ended September 30, 2022 and October 1, 2021. Reclassification of certain prior year amounts have been made to conform to current year presentation. Additionally, in the fourth quarter of 2021, Fortive adopted ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments in this update required that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, rather than at fair value as previously required under Topic 805. The amendments have been applied to all business combinations that occurred on or after January 1, 2021. The adoption only impacted the ServiceChannel acquisition which occurred in Q3 2021. Amounts previously reported for the three and nine month periods ended October 1, 2021 were retroactively adjusted to reflect a $1.5 million increase in both revenue and earnings as a result of the adoption of this pronouncement. Vontier Separation and Discontinued Operations On October 9, 2020, we completed the separation of Vontier Corporation (“Vontier”), the entity we created to hold our former Industrial Technologies segment (the “Separation”). The accounting requirements for reporting the Vontier business as a discontinued operation were met when the Separation was completed. Accordingly, the consolidated condensed financial statements reflect the results of separation activities associated with the prior Vontier business as a discontinued operation, which was immaterial for all periods presented. On January 19, 2021, we completed an exchange (the “Debt-for-Equity Exchange”) of 33.5 million shares of common stock of Vontier, representing all of the Retained Vontier Shares, for $1.1 billion in aggregate principal amount of indebtedness of the Company held by Goldman Sachs & Co. Interest expense and extinguishment costs related to the Debt-for-Equity Exchange during the first quarter of 2021 are included in continuing operations. Russia Ukraine Conflict In February 2022, Russian forces invaded Ukraine (“Russia Ukraine Conflict”) resulting in broad economic sanctions being imposed on Russia. In the second quarter of 2022, the Company exited business operations in Russia, other than for ASP’s sterilization products, which are exempt from international sanctions as humanitarian products. Our business in Russia and Ukraine accounted for less than 1% of total revenue and less than 0.2% of total assets for the fiscal year ended December 31, 2021. In the three and nine month periods ended September 30, 2022, the Company recorded pre-tax charges of $1.1 million and $17.3 million, respectively, primarily relating to the write-off of net assets, the write-off of the cumulative translation adjustment in earnings for legal entities deemed substantially liquidated, and to record provisions for employee severance and legal contingencies. These costs are identified as the “Russia exit and wind down costs” in the Condensed Consolidated Statements of Earnings. The total costs expected to be incurred in connection with the Russia exit are $18.4 million. Accumulated Other Comprehensive Income (Loss) Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. During the second quarter of 2022, we designated our ¥14.4 billion Yen-denominated variable interest rate term loan and our €275 million Euro-denominated variable interest rate term loan outstanding as net investment hedges of our investment in certain foreign operations. During the three and nine month periods ended September 30, 2022, we recognized after-tax foreign currency transaction gains of $14.6 million and $18.3 million, respectively, on the debt that were deferred in the foreign currency translation component of Accumulated other comprehensive income (loss) (“AOCI”) as an offset to the foreign currency translation adjustments on our investments in foreign subsidiaries. Any amounts deferred in AOCI will remain until the hedged investment is sold or substantially liquidated. We recorded no ineffectiveness from our net investment hedges during the three and nine month periods ended September 30, 2022. The changes in AOCI by component are summarized below ($ in millions): Foreign Pension adjustments (a) Total For the Three Months Ended September 30, 2022: Balance, July 1, 2022 $ (280.7) $ (61.4) $ (342.1) Other comprehensive income (loss) before reclassifications, net of income taxes (112.4) — (112.4) Amounts reclassified from accumulated other comprehensive income (loss): Increase (decrease) — 1.2 (b) 1.2 Income tax impact — (0.4) (0.4) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 0.8 0.8 Net current period other comprehensive income (loss), net of income taxes (112.4) 0.8 (111.6) Balance, September 30, 2022 $ (393.1) $ (60.6) $ (453.7) For the Three Months Ended October 1, 2021: Balance, July 2, 2021 $ (72.1) $ (85.2) $ (157.3) Other comprehensive income (loss) before reclassifications, net of income taxes (35.7) — (35.7) Amounts reclassified from accumulated other comprehensive income (loss): Increase (decrease) — 1.2 (b) 1.2 Income tax impact — (0.3) (0.3) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 0.9 0.9 Net current period other comprehensive income (loss), net of income taxes (35.7) 0.9 (34.8) Balance, October 1, 2021 $ (107.8) $ (84.3) $ (192.1) Foreign Pension adjustments (a) Total For the Nine Months Ended September 30, 2022: Balance, December 31, 2021 $ (122.7) $ (62.3) $ (185.0) Other comprehensive income (loss) before reclassifications, net of income taxes (273.1) — (273.1) Amounts reclassified from accumulated other comprehensive income (loss): Increase (decrease) 2.7 2.3 (b) 5.0 Income tax impact — (0.6) (0.6) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes 2.7 1.7 4.4 Net current period other comprehensive income (loss) (270.4) 1.7 (268.7) Balance, September 30, 2022 $ (393.1) $ (60.6) $ (453.7) For the Nine Months Ended October 1, 2021: Balance, December 31, 2020 $ (54.0) $ (87.1) $ (141.1) Other comprehensive income (loss) before reclassifications, net of income taxes (53.8) — (53.8) Amounts reclassified from accumulated other comprehensive income (loss): Increase (decrease) — 3.7 (b) 3.7 Income tax impact — (0.9) (0.9) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 2.8 2.8 Net current period other comprehensive income (loss) (53.8) 2.8 (51.0) Balance, October 1, 2021 $ (107.8) $ (84.3) $ (192.1) (a) Includes balances relating to defined benefit plans, supplemental executive retirement plans, and other postretirement employee benefit plans. (b) This component of AOCI is included in the computation of net periodic pension cost (refer to Note 12 in our most recently filed Form 10-K for additional details). Allowances for Doubtful Accounts All trade accounts and unbilled receivables are reported in the Consolidated Condensed Balance Sheet adjusted for any write-offs and net of allowances for credit losses. The allowances for credit losses represent management’s best estimate of the credit losses expected from our unbilled and trade accounts receivable portfolios over the life of the underlying assets. Additions to the allowances are charged to current period earnings, amounts determined to be uncollectible are charged directly against the allowances, while amounts recovered on previously written-off accounts increase the allowances. The following is a roll forward of the aggregated allowance for credit losses related to our trade accounts receivables as of September 30, 2022 ($ in millions): Balance, December 31, 2021 $ 39.7 Provision 10.9 Write-offs (7.7) Foreign currency exchange and other (1.4) Balance, September 30, 2022 $ 41.5 The allowance for unbilled receivables was immaterial for all periods presented. Recently Issued Accounting Standard In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which amends the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. On January 1, 2022, we adopted ASU 2020-06 using a modified retrospective approach and recognized in our balance sheet, as of January 1, 2022, a net of tax adjustment to reduce Additional Paid-in Capital by $65.7 million and increase debt by $3.7 million, with a corresponding net of tax adjustment to beginning retained earnings of $62.8 million. These adjustments are related to our 0.875% Convertible Senior Notes (the “Convertible Notes”), which were the only outstanding instruments impacted by the new standard at the time of adoption. Results for reporting periods beginning January 1, 2022 reflect the adoption of ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. Prior to our adoption of ASU 2020-06 on January 1, 2022, we recognized the fair value of the nonconvertible debt component of our Convertible Notes subject to the cash conversion guidance as debt and attributed the residual value to the conversion feature which was recognized in APIC. Subsequent to the issuance of our Convertible Notes in February 2019, we accreted the debt discount as non-cash interest expense in our Statements of Earnings. Further, we applied the treasury stock method to our Convertible Notes when calculating earnings per share (“EPS”) in all periods prior to our adoption of ASU 2020-06. After our adoption of ASU 2020-06, we account for convertible debt instruments wholly as debt, unless a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or a convertible debt instrument is issued at a substantial premium. On January 1, 2022, we reclassified the unamortized cost basis of our outstanding Convertible Notes wholly as debt, which subsequently matured and was settled on February 15, 2022. We applied the if-converted method to all convertible instruments when calculating EPS for the nine months ended September 30, 2022. As of September 30, 2022, we had no convertible instruments outstanding subject to the guidance in ASU 2020-06.

ACQUISITIONS AND DIVESTITURES

ACQUISITIONS AND DIVESTITURES	9 Months Ended
ACQUISITIONS AND DIVESTITURES	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
ACQUISITIONS AND DIVESTITURES	NOTE 2. ACQUISITIONS AND DIVESTITURES We continually evaluate potential mergers, acquisitions, and divestitures that align with our strategy and expedite the evolution of our portfolio of businesses into new and attractive areas. We have completed a number of acquisitions that have been accounted for as purchases of businesses and resulted in the recognition of goodwill in our financial statements. This goodwill arises because the purchase price for each acquired business reflects a number of factors, including the complementary fit, acceleration of our strategy and synergies the business brings with respect to our existing operations, the future earnings and cash flow potential of the business, the potential to add other strategically complementary acquisitions to the acquired business, the scarce or unique nature of the business in its markets, competition to acquire the business, the valuation of similar businesses in the marketplace (as reflected in a multiple of revenues, earnings, or cash flows), and the avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance our existing offerings to key target markets and develop new and profitable businesses. Acquisitions During the three and nine month periods ended September 30, 2022, insignificant adjustments were made to the purchase price allocation of prior year acquisitions, which are shown in Note 3. Provation On December 27, 2021, we acquired Provation Software, Inc. (“Provation”), a leading provider of clinical workflow software solutions used in hospitals and ambulatory surgery centers. The acquisition of Provation extends our digital offering and software capabilities in the healthcare space. The total consideration paid was approximately $1.4 billion, net of acquired cash and was primarily financed with proceeds from our financing activities and available cash. We recorded $977 million of goodwill related to the acquisition, which is not tax deductible. Provation had revenue in 2020 of approximately $90 million and is an operating company within our Advanced Healthcare Solutions segment. ServiceChannel On August 24, 2021, we acquired ServiceChannel Holdings, Inc. (“ServiceChannel”), a privately held, global provider of Software as a Service (“SaaS”) based multi-site facilities maintenance service solutions with an integrated service-provider network. The acquisition of ServiceChannel broadens our offering of software-enabled solutions for the facility and asset lifecycle workflow. The total consideration paid was approximately $1.2 billion, net of acquired cash, and included approximately $28 million of deferred compensation consideration that was recognized ratably over a twelve month service period. The ServiceChannel acquisition was primarily financed with available cash and proceeds from our financing activities. We recorded approximately $868 million of goodwill related to the acquisition, which is not tax deductible. ServiceChannel had revenue in 2020 of approximately $70 million and is an operating company within our Intelligent Operating Solutions segment. Revenue and operating losses attributable to the Provation and ServiceChannel acquisitions were $198.0 million and $38.0 million for the nine month period ended September 30, 2022. The operating losses include $57.9 million of intangible asset amortization and $18.8 million of transaction and integration costs, which were primarily comprised of employee compensation and retention costs and amounts paid to third party advisors, and are recorded in Selling, general and administration expenses, respectively. The following table summarizes the estimated fair value of the assets acquired and liabilities assumed from ServiceChannel and Provation as of September 30, 2022 ($ in millions): Provation ServiceChannel Total Accounts receivable $ 41.6 $ 10.1 $ 51.7 Goodwill 976.7 867.6 1,844.3 Other intangible assets, primarily customer relationships, technology, database, and trade names 586.5 342.9 929.4 Deferred revenue, current (50.2) (1.7) (51.9) Deferred tax liabilities (119.4) (41.9) (161.3) Other assets and liabilities, net (30.5) (10.7) (41.2) Net cash consideration $ 1,404.7 $ 1,166.3 $ 2,571.0 Divestitures

GOODWILL

GOODWILL	9 Months Ended
GOODWILL	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL	NOTE 3. GOODWILL The following is a roll forward of our carrying value of goodwill by segment ($ in millions): Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Total Goodwill Balance, December 31, 2021 $ 4,126.0 $ 1,840.0 $ 3,186.0 $ 9,152.0 Measurement period adjustments for 2021 acquisitions (5.9) — 8.4 2.5 Attributable to 2022 acquisitions and divestitures — 0.7 (2.6) (1.9) Foreign currency translation and other (79.1) (57.7) (38.3) (175.1) Balance, September 30, 2022 $ 4,041.0 $ 1,783.0 $ 3,153.5 $ 8,977.5

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
FAIR VALUE MEASUREMENTS	Sep. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 4. FAIR VALUE MEASUREMENTS Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where our assets and liabilities are required to be carried at fair value, and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1 inputs are quoted prices (unadjusted) for identical assets or liabilities in active markets. • Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation. • Level 3 inputs are unobservable inputs based on our assumptions. The classification of a financial asset or liability within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Below is a summary of financial liabilities that are measured at fair value on a recurring basis ($ in millions): Quoted Prices Significant Other Significant Total September 30, 2022 Deferred compensation liabilities $ — $ 29.7 $ — $ 29.7 December 31, 2021 Deferred compensation liabilities — 36.0 — 36.0 Certain management employees participate in our nonqualified deferred compensation programs that permit such employees to defer a portion of their compensation, on a pretax basis, until after their termination of employment. All amounts deferred under such plans are unfunded, unsecured obligations and are presented as a component of our compensation and benefits accrual included in Other long-term liabilities in the Consolidated Condensed Balance Sheets. Participants may choose among alternative earnings rates for the amounts they defer, which are primarily based on investment options within our defined contribution plans for the benefit of U.S. employees (except that the earnings rates for amounts contributed unilaterally by the Company are entirely based on changes in the value of Fortive common stock). Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable earnings rates. Non-recurring Fair Value Measurements Certain non-financial assets, primarily property, plant, and equipment, goodwill, and intangible assets, are not required to be measured at fair value on a recurring basis and are reported at their carrying value. However, these assets are required to be assessed for impairment whenever events or circumstances indicate that their carrying value may not be fully recoverable, and at least annually for goodwill and indefinite-lived intangible assets. We evaluated events and circumstances that, as of September 30, 2022, indicated the carrying value of an equity investment in a third-party entity held by our Intelligent Operating Solutions segment was no longer recoverable. As a result, in the three and nine month periods ended September 30, 2022, we recorded a pre-tax impairment loss of $8.1 million to write down the investment to fair value. The loss was recorded in “Other non-operating expense, net” in our Consolidated Condensed Statement of Earnings. Fair Value of Financial Instruments The carrying amount and fair value of financial instruments are as follows ($ in millions): September 30, 2022 December 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Current portion of long-term debt $ 999.9 $ 1,000.0 $ 2,151.7 $ 2,158.3 Long-term debt, net of current maturities 2,559.0 2,381.0 1,807.3 1,978.9 As of September 30, 2022 and December 31, 2021, the current portion of long-term debt and long-term debt, net of current maturities were categorized as Level 1. The fair values of long-term borrowings were based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings may be attributable to changes in market interest rates and/or our credit ratings subsequent to the borrowing. The fair value of cash and cash equivalents, trade accounts receivable, net, trade accounts payable, and commercial paper approximates their carrying value due to the short-term maturities of these instruments.

FINANCING AND CAPITAL

FINANCING AND CAPITAL	9 Months Ended
FINANCING AND CAPITAL	Sep. 30, 2022
Debt Disclosure [Abstract]
FINANCING AND CAPITAL	NOTE 5. FINANCING AND CAPITAL The carrying value of the components of our long-term debt were as follows ($ in millions): September 30, 2022 December 31, 2021 U.S. dollar-denominated commercial paper $ 747.3 $ 364.9 Delayed-Draw Term Loan due 2022 999.9 999.7 Yen Term Loan due 2025 99.5 — Euro Term Loan due 2025 269.0 — 3.15% senior unsecured notes due 2026 895.9 895.1 4.30% senior unsecured notes due 2046 547.3 547.3 0.875% senior convertible notes due 2022 — 1,152.0 Long-term debt 3,558.9 3,959.0 Less: current portion of long-term debt 999.9 2,151.7 Long-term debt, net of current maturities $ 2,559.0 $ 1,807.3 Aggregate unamortized debt discounts, premiums, and issuance costs of $8.1 million and $13.0 million as of September 30, 2022 and December 31, 2021, respectively, are netted against the principal amounts of the components of debt in the table above. Refer to Note 11 of our 2021 Annual Report on Form 10-K for further details of our debt financing. Yen Term Loan On June 17, 2022, we entered into a three-year, ¥14.4 billion senior unsecured term facility (“Yen Term Loan”). On the same day, we drew and converted the entire available balance under the facility, which yielded net proceeds of $107 million. The Yen Term Loan is due on June 17, 2025 and is pre-payable at our option. The Yen Term Loan bears interest at a rate of Tokyo Term Risk Free Rate (“TORF”), plus 65 basis points; provided, however, that the TORF may not be less than zero for the Yen Term Loan. Euro Term Loan On June 21, 2022, we entered into a three-year €275 million senior unsecured term facility (“Euro Term Loan”). On June 28, 2022, we drew and converted the entire available balance under the facility, which yielded net proceeds of $290 million. The Euro Term Loan is due on June 23, 2025 and is pre-payable at our option. The Euro Term Loan bears interest at a rate of Euro Interbank Offered Rate (“Euribor”), plus 55 basis points; provided, however that the Euribor may not be less than zero for the Euro Term Loan. Convertible Senior Notes On February 22, 2019, we issued $1.4 billion in aggregate principal amount of our 0.875% Convertible Senior Notes due 2022, including $187.5 million in aggregate principal amount resulting from an exercise in full of an over-allotment option. The Convertible Notes were issued in a private placement to certain initial purchasers for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Of the $1.4 billion in principal amount from the issuance of the Convertible Notes, $1.3 billion was classified as debt and $102.2 million was classified as equity, using an assumed effective interest rate of 3.38%. Debt issuance costs of $24.3 million were proportionately allocated to debt and equity. On February 9, 2021, we repurchased $281 million of the Convertible Notes at fair value using the remaining cash proceeds received from Vontier in the Vontier Separation and other cash on hand. In connection with the repurchase, we recorded a loss on debt extinguishment during the nine month period ended October 1, 2021 of $10.5 million. In addition, upon repurchase we recorded $11.6 million as a reduction to additional paid-in capital related to the equity component of the repurchased Convertible Notes. On January 1, 2022, we adopted ASU 2020-06, as further detailed in Note 1. We reclassified the carrying value of the instrument wholly to debt, eliminating the value formerly attributable to the conversion feature and the associated debt issuance costs that were previously classified as equity. On February 15, 2022, the maturity date of the Convertible Notes, Fortive repaid, in cash, $1.2 billion in outstanding principal and accrued interest thereon. We recognized $2.1 million in interest expense during the nine month period ended September 30, 2022, of which $1.3 million was related to the contractual coupon rate of 0.875% and $0.8 million was attributable to the amortization of debt issuance costs for each respective period. We recognized $11.1 million and $34.5 million in interest expense during the three and nine month period ended October 1, 2021, of which $2.5 million and $7.9 million was related to the contractual coupon rate of 0.875%, $1.5 million and $4.7 million was attributable to the amortization of debt issuance costs, and $7.1 million and $21.9 million was attributable to the amortization of the discount for each respective period. Other Liquidity Sources We generally satisfy any short-term liquidity needs that are not met through operating cash flows and available cash primarily through issuances of commercial paper under our U.S. dollar and Euro-denominated commercial paper programs (“Commercial Paper Programs”). Under these programs, we may issue unsecured promissory notes with maturities not exceeding 397 and 183 days, respectively. Interest expense on commercial paper is paid at maturity and is generally based on our credit ratings at the time of issuance and prevailing short-term interest rates. The details of our outstanding Commercial Paper Programs as of September 30, 2022 were as follows ($ in millions): Carrying value Annual effective rate Weighted average remaining maturity (in days) U.S. dollar-denominated commercial paper $ 747.3 3.19 % 29 Credit support for the Commercial Paper Programs is provided by a five-year $2.0 billion senior unsecured revolving credit facility that expires on November 30, 2023 (the “Revolving Credit Facility”) which, to the extent not otherwise providing credit support for our commercial paper programs, can also be used for working capital and other general corporate purposes. As of September 30, 2022, no borrowings were outstanding under the Revolving Credit Facility. We classified our borrowings outstanding under the Commercial Paper Programs as Long-term debt in the accompanying Consolidated Condensed Balance Sheets as we had the intent and ability, as supported by availability under the Revolving Credit Facility, to refinance these borrowings for at least one year from the balance sheet date. Debt-for-Equity Exchange On January 19, 2021, we completed the Debt-for-Equity Exchange of 33.5 million shares of common stock of Vontier, representing all of the Retained Vontier Shares, for $1.1 billion in aggregate principal amount of indebtedness of the Company. During the first quarter of 2021 we recognized a gain of $57.0 million related to the subsequent change in the fair value of the Retained Vontier Shares. We recorded a loss on extinguishment of the debt included in the Debt-for-Equity Exchange of $94.4 million in the nine month period ended October 1, 2021. Subsequent Events On October 18, 2022, we entered into a second amended and restated credit agreement (the “Amended and Restated Credit Agreement”) extending the availability period of the Revolving Credit Facility to October 18, 2027 with an additional two one year extension options at our request and with the consent of the lenders. The Amended and Restated Credit Agreement also contains an option permitting us to request an increase in the amounts available under the Revolving Credit Facility of up to an aggregate additional $1.0 billion. We are obligated to pay an annual facility fee for the Revolving Credit Facility of between 6.5 and 15 basis points varying according to our long-term debt credit rating. Borrowings under the new Revolving Credit Facility in U.S Dollars bear interest at a rate equal, at our option, to either (1) Term Secured Overnight Financing Rate (“Term SOFR”), plus a 10 basis points Credit Spread Adjustment (“CSA”) plus a margin of between 68.5 and 110.0 basis points, depending on our long-term debt credit rating or (2) the highest of (a) the Federal funds rate plus 50 basis points, (b) the prime rate, (c) Term SOFR plus 100 basis points and (d) 1.0%, plus in each case a margin between zero and 10 basis points depending on our long-term debt credit rating. In addition, beginning with our 2023 performance relative to our annual greenhouse gas reduction targets, the interest rate on any borrowings can increase or decrease by 4.0 basis points and the facility fee can increase or decrease by 1.0 basis points, for a maximum impact of an increase or decrease of 5.0 basis points. The Amended and Restated Credit Agreement requires us to maintain a consolidated net leverage ratio of debt to consolidated EBITDA (as defined in the Credit Agreement) of less than 3.5 to 1.0. The maximum consolidated net leverage ratio will be increased to 4.0 to 1.0 for the four consecutive full fiscal quarters immediately following the consummation of any acquisition by us in which the purchase price exceeds $250 million. The Amended and Restated Credit Agreement also contains customary representations, warranties, conditions precedent, events of default, indemnities, and affirmative and negative covenants. On October 18, 2022, we entered into a $1.0 billion delayed-draw senior unsecured term facility (“Delayed-Draw Term Loan Due 2023”). We intend to use proceeds of the Delayed-Draw Term Loan Due 2023 to repay the outstanding principal balance of the Delayed-Draw Term Loan Due 2022, which matures in December 2022. The Delayed-Draw Term Loan Due 2023 bears interest at a variable rate equal to Term SOFR plus a CSA of 10 basis points plus a spread of 82.5 basis points at our current credit rating. Borrowing under the Term Loan Due 2023 are prepayable at our option in whole or in part without premium or penalty and amounts borrowed may not be reborrowed once repaid.

SALES

SALES	9 Months Ended
SALES	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
SALES	NOTE 6. SALES We derive revenue primarily from the sale of products and software, and services. Revenue is recognized when control of promised products or services is transferred to customers in an amount that reflects the consideration we expect to be entitled to in exchange for those products, software, or services. Product sales include revenue from the sale of products and equipment, which includes our software and SaaS product offerings and equipment rentals. Service sales include revenues from extended warranties, post-contract customer support (“PCS”), maintenance contracts or services, contract labor to perform ongoing service at a customer location, and services related to previously sold products. Contract Assets — In certain circumstances, we record contract assets which include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customer, and right to payment is not only subject to the passage of time. Contract assets were $84 million as of September 30, 2022 and $71 million as of December 31, 2021. Contract Costs — We incur and capitalize direct incremental costs to obtain certain contracts, typically sales-related commissions and costs associated with assets used by our customers in certain software arrangements. Deferred sales-related commissions are not capitalized when the amortization period is one year or less, as we elected to use the practical expedient to expense these sales commissions as incurred. As of September 30, 2022 and December 31, 2021, we had $37 million and $27 million, respectively, in net revenue-related contract costs primarily related to certain software contracts. Revenue-related contract costs are recorded in the Prepaid expenses and other current assets and Other assets line items in our Consolidated Condensed Balance Sheets. These assets have estimated useful lives between three Contract Liabilities — Our contract liabilities consist of deferred revenue generally related to subscription-based software contracts, PCS and extended warranty sales, where in most cases we receive up-front payment and recognize revenue over the service or support term. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Consolidated Condensed Balance Sheets. Our contract liabilities consisted of the following ($ in millions): September 30, 2022 December 31, 2021 Deferred revenue - current $ 472.2 $ 457.6 Deferred revenue - noncurrent 35.2 33.8 Total contract liabilities $ 507.4 $ 491.4 During the three and nine month period ended September 30, 2022, we recognized revenue related to our contract liabilities at December 31, 2021 of $63 million and $319 million, respectively. The change in our contract liabilities from December 31, 2021 to September 30, 2022 was primarily due to the timing of billings and recognition as revenue of subscription-based software contracts, PCS and extended warranty services. Remaining Performance Obligations — Our remaining performance obligations represent the transaction price of firm, non-cancelable orders and the average contract value for software contracts, for which work has not been performed. We have excluded performance obligations with an original expected duration of one year or less from the amounts below. The aggregate remaining performance obligations attributable to each of our segments is as follows ($ in millions): September 30, 2022 Intelligent Operating Solutions $ 584.2 Precision Technologies 50.4 Advanced Healthcare Solutions 68.5 Total remaining performance obligations $ 703.1 The majority of remaining performance obligations are related to service and support contracts, which we expect to fulfill approximately 80 percent within the next two years, approximately 90 percent within the next three years, and substantially all within four years. Disaggregation of Revenue We disaggregate revenue from contracts with customers by sales of products and software and services, geographic location, and end market for each of our segments, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. Disaggregation of revenue for the three month period ended September 30, 2022 is presented as follows ($ in millions): Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Sales: Sales of products and software $ 1,227.7 $ 519.2 $ 467.3 $ 241.2 Sales of services 228.3 94.5 56.4 77.4 Total $ 1,456.0 $ 613.7 $ 523.7 $ 318.6 Geographic: United States $ 799.0 $ 342.0 $ 267.8 $ 189.2 China 186.0 56.6 102.6 26.8 All other (each country individually less than 5% of total sales) 471.0 215.1 153.3 102.6 Total $ 1,456.0 $ 613.7 $ 523.7 $ 318.6 End markets: (a) Direct sales: Healthcare $ 354.1 $ 11.1 $ 42.1 $ 300.9 Industrial & Manufacturing 334.5 217.6 111.3 5.6 Utilities & Power 93.1 45.5 47.6 — Government 122.7 65.5 48.7 8.5 Communications, Electronics & Semiconductor 111.3 24.5 86.4 0.4 Aerospace & Defense 66.9 0.1 66.8 — Oil & Gas 66.4 65.3 1.1 — Retail & Consumer 83.9 61.7 22.2 — Other 166.3 91.2 75.1 — Total direct sales 1,399.2 582.5 501.3 315.4 Distributors 56.8 31.2 22.4 3.2 Total $ 1,456.0 $ 613.7 $ 523.7 $ 318.6 (a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer. Disaggregation of revenue for the three month period ended October 1, 2021 is presented as follows ($ in millions): Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Sales: Sales of products and software $ 1,107.1 $ 464.2 $ 401.0 $ 241.9 Sales of services 193.9 72.7 54.7 66.5 Total $ 1,301.0 $ 536.9 $ 455.7 $ 308.4 Geographic: United States $ 685.2 $ 285.3 $ 234.6 $ 165.3 China 154.8 48.8 75.8 30.2 All other (each country individually less than 5% of total sales) 461.0 202.8 145.3 112.9 Total $ 1,301.0 $ 536.9 $ 455.7 $ 308.4 End markets: (a) Direct sales: Healthcare $ 327.6 $ 10.5 $ 30.7 $ 286.4 Industrial & Manufacturing 313.5 204.4 103.2 5.9 Utilities & Power 97.3 55.3 42.0 — Government 100.1 54.6 33.4 12.1 Communications, Electronics & Semiconductor 103.4 30.6 72.3 0.5 Aerospace & Defense 60.6 — 60.6 — Oil & Gas 64.6 62.4 2.2 — Retail & Consumer 53.6 33.0 20.6 — Other 117.7 56.5 61.1 0.1 Total direct sales 1,238.4 507.3 426.1 305.0 Distributors 62.6 29.6 29.6 3.4 Total $ 1,301.0 $ 536.9 $ 455.7 $ 308.4 (a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer. Disaggregation of revenue for the nine month period ended September 30, 2022 is presented as follows ($ in millions): Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Sales: Sales of products and software $ 3,609.8 $ 1,553.9 $ 1,322.6 $ 733.3 Sales of services 686.0 277.5 162.6 245.9 Total $ 4,295.8 $ 1,831.4 $ 1,485.2 $ 979.2 Geographic: United States $ 2,317.9 $ 1,005.0 $ 751.4 $ 561.5 China 514.1 160.6 273.5 80.0 All other (each country individually less than 5% of total sales) 1,463.8 665.8 460.3 337.7 Total $ 4,295.8 $ 1,831.4 $ 1,485.2 $ 979.2 End markets: (a) Direct sales: Healthcare $ 1,077.2 $ 34.6 $ 120.5 $ 922.1 Industrial & Manufacturing 998.3 656.1 322.7 19.5 Utilities & Power 273.4 136.4 137.0 — Government 338.5 177.6 134.8 26.1 Communications, Electronics & Semiconductor 301.2 74.6 225.2 1.4 Aerospace & Defense 187.0 0.4 186.6 — Oil & Gas 199.8 193.4 6.4 — Retail & Consumer 249.5 186.0 63.5 — Other 478.7 268.8 209.8 0.1 Total direct sales 4,103.6 1,727.9 1,406.5 969.2 Distributors 192.2 103.5 78.7 10.0 Total $ 4,295.8 $ 1,831.4 $ 1,485.2 $ 979.2 (a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer. Disaggregation of revenue for the nine month period ended October 1, 2021 is presented as follows ($ in millions): Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Sales: Sales of products and software $ 3,320.3 $ 1,395.6 $ 1,211.6 $ 713.1 Sales of services 559.6 194.0 163.4 202.2 Total $ 3,879.9 $ 1,589.6 $ 1,375 $ 915.3 Geographic: United States $ 1,977.6 $ 810.2 $ 690.0 $ 477.4 China 482.6 162.0 234.3 86.3 All other (each country individually less than 5% of total sales) 1,419.7 617.4 450.7 351.6 Total $ 3,879.9 $ 1,589.6 $ 1,375.0 $ 915.3 End markets: (a) Direct sales: Healthcare $ 983.0 $ 28.3 $ 99.6 $ 855.1 Industrial & Manufacturing 927.9 601.6 308.6 17.7 Utilities & Power 290.0 166.8 123.2 — Government 287.0 150.7 105.7 30.6 Communications, Electronics & Semiconductor 288.8 90.9 196.2 1.7 Aerospace & Defense 181.7 — 181.7 — Oil & Gas 194.6 186.9 7.7 — Retail & Consumer 143.7 75.2 68.5 — Other 379.9 184.3 195.5 0.1 Total direct sales 3,676.6 1,484.7 1,286.7 905.2 Distributors 203.3 104.9 88.3 10.1 Total $ 3,879.9 $ 1,589.6 $ 1,375.0 $ 915.3 (a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.

INCOME TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 7. INCOME TAXES Our effective tax rates for the three and nine month periods ended September 30, 2022 were 12.7% and 14.4%, respectively, as compared to 13.1% and 11.1%, respectively, for the three and nine month periods ended October 1, 2021. The year-over-year decrease in the effective tax rate for the three month period ended September 30, 2022 was relatively consistent as compared to the three month period ended October 1, 2021. The year-over-year increase in the effective tax rate for the nine month period ended September 30, 2022 as compared to the nine month period ended October 1, 2021 was primarily due to a non-recurring permanent difference on the Q1 2021 gain on our Retained Vontier Shares as a result of the tax-free treatment of our disposition of the shares through the Debt-for-Equity Exchange and the effect of Russia exit including wind down costs for which no tax benefit was recognized. Our effective tax rate for the three and nine month periods ended September 30, 2022 differs from the U.S. federal statutory rate of 21% due primarily to the positive and negative effects of the Tax Cuts and Jobs Act, U.S. federal permanent differences, the impacts of credits and deductions provided by law, an increase to in our uncertain tax positions relating to higher interest rates, and the effect of Russia exit and wind down costs for which no tax benefit was recognized.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
STOCK-BASED COMPENSATION	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 8. STOCK-BASED COMPENSATION Our stock-based compensation program (the “Stock Plan”) provides for the grant of stock appreciation rights, performance stock units, restricted stock units, restricted stock awards, and performance stock awards (collectively, “Stock Awards”), stock options, or any other stock-based award. As of September 30, 2022, approximately 16 million shares of our common stock were available for subsequent issuance under the Stock Plan. For a full description of our stock-based compensation program refer to Note 17 of our 2021 Annual Report on Form 10-K. Stock-based Compensation Expense Stock-based compensation has been recognized as a component of Selling, general and administrative expenses in the Consolidated Condensed Statements of Earnings based on the portion of the awards that are ultimately expected to vest. The following summarizes the components of our stock-based compensation expense under the Stock Plan ($ in millions): Three Months Ended Nine Months Ended September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 Stock Awards: Pretax compensation expense $ 14.3 $ 11.3 $ 43.0 $ 34.0 Income tax benefit (2.6) (2.1) (7.3) (5.9) Stock Award expense, net of income taxes 11.7 9.2 35.7 28.1 Stock options: Pretax compensation expense 8.6 7.1 24.9 21.2 Income tax benefit (1.4) (1.3) (3.8) (3.8) Stock option expense, net of income taxes 7.2 5.8 21.1 17.4 Total stock-based compensation: Pretax compensation expense 22.9 18.4 67.9 55.2 Income tax benefit (4.0) (3.4) (11.1) (9.7) Total stock-based compensation expense, net of income taxes $ 18.9 $ 15.0 $ 56.8 $ 45.5 The following summarizes the unrecognized compensation cost for the Stock Plan awards as of September 30, 2022. This compensation cost is expected to be recognized over a weighted average period of approximately two years, representing the remaining service period related to the awards. Future compensation amounts will be adjusted for any changes in estimated forfeitures ($ in millions): Stock Awards $ 106.6 Stock options 52.7 Total unrecognized compensation cost $ 159.3

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9. COMMITMENTS AND CONTINGENCIES For a description of our litigation and contingencies and additional information about our leases, refer to Note 16 and Note 10, respectively, in our 2021 Annual Report on Form 10-K. Warranty We generally accrue estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly, and appropriately maintained. Warranty period terms depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor, and, in certain instances, estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known. The following is a roll forward of our accrued warranty liability ($ in millions): Balance, December 31, 2021 $ 25.2 Accruals for warranties issued during the period 12.3 Settlements made (14.1) Effect of foreign currency translation and other (0.4) Balance, September 30, 2022 $ 23.0 Leases

NET EARNINGS PER SHARE

NET EARNINGS PER SHARE	9 Months Ended
NET EARNINGS PER SHARE	Sep. 30, 2022
Earnings Per Share [Abstract]
NET EARNINGS PER SHARE	NOTE 10. NET EARNINGS PER SHARE Basic net EPS is calculated by dividing net earnings attributable to common stockholders by the weighted average number of shares of common stock outstanding for the applicable period. Diluted EPS is similarly calculated, except that the calculation includes the dilutive effect of the assumed conversion of Convertible Notes and associated issuance of shares under the if-converted method and the assumed issuance of shares under stock-based compensation plans under the treasury stock method, except where the inclusion of such shares would have an anti-dilutive impact. Anti-dilutive options excluded from the diluted EPS calculation for the three and nine month periods ended September 30, 2022 were both 7.3 million, and were 0.2 million and 0.3 million for the three and nine month periods ended October 1, 2021, respectively. As described in Note 5, upon conversion of the Convertible Notes, holders were entitled to receive cash, shares of our common stock, or a combination thereof, at our election. As described in Note 1, prior to our adoption of ASU 2020-06 on January 1, 2022, we accounted for the conversion feature under the treasury stock method in our calculation of EPS since we intended and had the ability to settle such conversions through cash up to the principal amount of the Convertible Notes and, if applicable, through shares of our common stock for conversion value, if any, in excess of the principal amount of the Convertible Notes. Because the fair value of our common stock was below the conversion price, the Convertible Notes had no impact on our earnings per share for the nine month period ended October 1, 2021. Upon adopting ASU 2020-06 on January 1, 2022, we accounted for the Convertible Notes under the if-converted method in our calculation of diluted EPS, as required under the new guidance. On July 1, 2021, all outstanding shares of our 5.0% Mandatory Convertible Preferred Stock (“MCPS”) converted at a rate of 14.0978 common shares per share of preferred stock into an aggregate of approximately 19.4 million shares (net of fractional shares) of the Company’s common stock, pursuant to the terms of the Certificate of Designation governing the Series A Preferred Stock. Fortive issued cash in lieu of fractional shares of common stock in the conversion. These payments were recorded as a reduction to additional paid-in capital. The impact of the MCPS calculated under the if-converted method was anti-dilutive for the periods in 2021 prior to conversion. Information related to the calculation of net earnings per share of common stock is summarized as follows ($ and shares in millions, except per share amounts): Three Months Ended Nine Months Ended September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 Numerator Net earnings from continuing operations $ 189.9 $ 152.6 $ 528.0 $ 446.3 Mandatory convertible preferred stock cumulative dividends — — — (34.5) Convertible note interest add-back (if converted method) — — 1.8 — Diluted Net Earnings from Continuing Operations $ 189.9 $ 152.6 $ 529.8 $ 411.8 Denominator Weighted average common shares outstanding used in basic earnings per share 355.2 358.9 357.3 345.6 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive Stock Awards 2.7 3.3 2.6 3.2 Conversion of convertible notes (if converted method) — — 2.1 — Weighted average common shares outstanding used in diluted earnings per share 357.9 362.2 362.0 348.8 Net earnings from continuing operations per common share - Basic $ 0.53 $ 0.42 $ 1.48 $ 1.19 Net earnings from continuing operations per common share - Diluted $ 0.53 $ 0.42 $ 1.46 $ 1.18 We declared and paid cash dividends per common share for the periods as presented below. We declared and paid the MCPS dividend in the first quarter of 2021, and declared and paid the final dividend in the second quarter of 2021. Dividend Per Amount Dividend per MCPS Amount 2022: First quarter $ 0.07 $ 25.1 $ — $ — Second quarter 0.07 24.9 — — Third quarter 0.07 24.8 — — Total $ 0.21 $ 74.8 $ — $ — 2021: First quarter $ 0.07 $ 23.7 $ 12.5 $ 17.3 Second quarter 0.07 23.7 12.5 17.2 Third quarter 0.07 25.2 — — Total $ 0.21 $ 72.6 $ 25.0 $ 34.5 * The sum of the components of total dividends paid may not equal the total amount due to rounding.

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
SEGMENT INFORMATION	Sep. 30, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	NOTE 11. SEGMENT INFORMATION We report our results in three separate business segments consisting of Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. Our Intelligent Operating Solutions segment provides leading workflow solutions to accelerate industrial and facility reliability and performance, as well as compliance and safety across a range of vertical end markets, including manufacturing, process industries, healthcare, utilities and power, communications and electronics, among others. We provide differentiated instrumentation and sensors, software and services to address our customers’ toughest workflow challenges. Our Precision Technologies segment supplies instrumentation and sensing technologies to a broad set of vertical end markets, enabling our customers to accelerate the development, manufacture and launch of innovative products and solutions. We provide our customers with electrical test and measurement instruments and services, energetic material devices, and a broad portfolio of sensor and control system solutions. Our Advanced Healthcare Solutions segment supplies critical workflow solutions to hospitals and other healthcare customers, enabling safer, more efficient, and higher quality healthcare. We provide hardware, consumables, software and services that optimize our customers’ most critical workflows, including instrument sterilization and device reprocessing, instrument tracking, cell therapy equipment design and manufacturing, biomedical test tools, radiation safety monitoring, end-to-end clinical productivity solutions and asset management. Our chief operating decision maker (“CODM”) assesses performance and allocates resources based on our operating segments, which are also our reportable segments. Operating profit amounts in the Other category and Russia exit and wind down costs consist of unallocated corporate costs and other costs not utilized or reviewed by our CODM at a segment level in evaluating segment operating performance. Our segment results are as follows ($ in millions): Three Months Ended Nine Months Ended September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 Sales: Intelligent Operating Solutions $ 613.7 $ 536.9 $ 1,831.4 $ 1,589.6 Precision Technologies 523.7 455.7 1,485.2 1,375.0 Advanced Healthcare Solutions 318.6 308.4 979.2 915.3 Total $ 1,456.0 $ 1,301.0 $ 4,295.8 $ 3,879.9 Operating Profit: Intelligent Operating Solutions $ 132.1 $ 91.5 $ 369.0 $ 314.9 Precision Technologies 131.8 101.1 348.5 301.1 Advanced Healthcare Solutions 17.3 34.4 73.4 75.8 Other (28.2) (24.7) (77.1) (80.6) Russia exit and wind down costs (1.1) — (17.3) — Total Operating Profit 251.9 202.3 696.5 611.2 Interest expense, net (26.4) (25.1) (66.2) (78.0) Loss on extinguishment of debt — — — (104.9) Gain on investment in Vontier Corporation — — — 57.0 Gain on litigation resolution — — — 26.0 Other non-operating expense, net (8.0) (1.6) (13.8) (9.5) Earnings from continuing operations before income taxes $ 217.5 $ 175.6 $ 616.5 $ 501.8

BUSINESS OVERVIEW (Policies)

BUSINESS OVERVIEW (Policies)	9 Months Ended
BUSINESS OVERVIEW (Policies)	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. During the second quarter of 2022, we designated our ¥14.4 billion Yen-denominated variable interest rate term loan and our €275 million Euro-denominated variable interest rate term loan outstanding as net investment hedges of our investment in certain foreign operations. During the three and nine month periods ended September 30, 2022, we recognized after-tax foreign currency transaction gains of $14.6 million and $18.3 million, respectively, on the debt that were deferred in the foreign currency translation component of Accumulated other comprehensive income (loss) (“AOCI”) as an offset to the foreign currency translation adjustments on our investments in foreign subsidiaries. Any amounts deferred in AOCI will remain until the hedged investment is sold or substantially liquidated. We recorded no ineffectiveness from our net investment hedges during the three and nine month periods ended September 30, 2022.
Allowances for Doubtful Accounts	Allowances for Doubtful AccountsAll trade accounts and unbilled receivables are reported in the Consolidated Condensed Balance Sheet adjusted for any write-offs and net of allowances for credit losses. The allowances for credit losses represent management’s best estimate of the credit losses expected from our unbilled and trade accounts receivable portfolios over the life of the underlying assets. Additions to the allowances are charged to current period earnings, amounts determined to be uncollectible are charged directly against the allowances, while amounts recovered on previously written-off accounts increase the allowances.
Recently Issued Accounting Standard	Recently Issued Accounting Standard In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which amends the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. On January 1, 2022, we adopted ASU 2020-06 using a modified retrospective approach and recognized in our balance sheet, as of January 1, 2022, a net of tax adjustment to reduce Additional Paid-in Capital by $65.7 million and increase debt by $3.7 million, with a corresponding net of tax adjustment to beginning retained earnings of $62.8 million. These adjustments are related to our 0.875% Convertible Senior Notes (the “Convertible Notes”), which were the only outstanding instruments impacted by the new standard at the time of adoption. Results for reporting periods beginning January 1, 2022 reflect the adoption of ASU 2020-06, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. Prior to our adoption of ASU 2020-06 on January 1, 2022, we recognized the fair value of the nonconvertible debt component of our Convertible Notes subject to the cash conversion guidance as debt and attributed the residual value to the conversion feature which was recognized in APIC. Subsequent to the issuance of our Convertible Notes in February 2019, we accreted the debt discount as non-cash interest expense in our Statements of Earnings. Further, we applied the treasury stock method to our Convertible Notes when calculating earnings per share (“EPS”) in all periods prior to our adoption of ASU 2020-06. After our adoption of ASU 2020-06, we account for convertible debt instruments wholly as debt, unless a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or a convertible debt instrument is issued at a substantial premium. On January 1, 2022, we reclassified the unamortized cost basis of our outstanding Convertible Notes wholly as debt, which subsequently matured and was settled on February 15, 2022. We applied the if-converted method to all convertible instruments when calculating EPS for the nine months ended September 30, 2022. As of September 30, 2022, we had no convertible instruments outstanding subject to the guidance in ASU 2020-06.
Fair Value Measurements	Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where our assets and liabilities are required to be carried at fair value, and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1 inputs are quoted prices (unadjusted) for identical assets or liabilities in active markets. • Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation. • Level 3 inputs are unobservable inputs based on our assumptions. The classification of a financial asset or liability within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety.
Sales	We derive revenue primarily from the sale of products and software, and services. Revenue is recognized when control of promised products or services is transferred to customers in an amount that reflects the consideration we expect to be entitled to in exchange for those products, software, or services. Product sales include revenue from the sale of products and equipment, which includes our software and SaaS product offerings and equipment rentals. Service sales include revenues from extended warranties, post-contract customer support (“PCS”), maintenance contracts or services, contract labor to perform ongoing service at a customer location, and services related to previously sold products. Contract Assets — In certain circumstances, we record contract assets which include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customer, and right to payment is not only subject to the passage of time. Contract assets were $84 million as of September 30, 2022 and $71 million as of December 31, 2021. Contract Costs — We incur and capitalize direct incremental costs to obtain certain contracts, typically sales-related commissions and costs associated with assets used by our customers in certain software arrangements. Deferred sales-related commissions are not capitalized when the amortization period is one year or less, as we elected to use the practical expedient to expense these sales commissions as incurred. As of September 30, 2022 and December 31, 2021, we had $37 million and $27 million, respectively, in net revenue-related contract costs primarily related to certain software contracts. Revenue-related contract costs are recorded in the Prepaid expenses and other current assets and Other assets line items in our Consolidated Condensed Balance Sheets. These assets have estimated useful lives between three Contract Liabilities — Our contract liabilities consist of deferred revenue generally related to subscription-based software contracts, PCS and extended warranty sales, where in most cases we receive up-front payment and recognize revenue over the service or support term. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Consolidated Condensed Balance Sheets. Remaining Performance Obligations — Our remaining performance obligations represent the transaction price of firm, non-cancelable orders and the average contract value for software contracts, for which work has not been performed. We have excluded performance obligations with an original expected duration of one year or less from the amounts below.

BUSINESS OVERVIEW (Tables)

BUSINESS OVERVIEW (Tables)	9 Months Ended
BUSINESS OVERVIEW (Tables)	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Reclassification of Accumulated Other Comprehensive Income	The changes in AOCI by component are summarized below ($ in millions): Foreign Pension adjustments (a) Total For the Three Months Ended September 30, 2022: Balance, July 1, 2022 $ (280.7) $ (61.4) $ (342.1) Other comprehensive income (loss) before reclassifications, net of income taxes (112.4) — (112.4) Amounts reclassified from accumulated other comprehensive income (loss): Increase (decrease) — 1.2 (b) 1.2 Income tax impact — (0.4) (0.4) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 0.8 0.8 Net current period other comprehensive income (loss), net of income taxes (112.4) 0.8 (111.6) Balance, September 30, 2022 $ (393.1) $ (60.6) $ (453.7) For the Three Months Ended October 1, 2021: Balance, July 2, 2021 $ (72.1) $ (85.2) $ (157.3) Other comprehensive income (loss) before reclassifications, net of income taxes (35.7) — (35.7) Amounts reclassified from accumulated other comprehensive income (loss): Increase (decrease) — 1.2 (b) 1.2 Income tax impact — (0.3) (0.3) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 0.9 0.9 Net current period other comprehensive income (loss), net of income taxes (35.7) 0.9 (34.8) Balance, October 1, 2021 $ (107.8) $ (84.3) $ (192.1) Foreign Pension adjustments (a) Total For the Nine Months Ended September 30, 2022: Balance, December 31, 2021 $ (122.7) $ (62.3) $ (185.0) Other comprehensive income (loss) before reclassifications, net of income taxes (273.1) — (273.1) Amounts reclassified from accumulated other comprehensive income (loss): Increase (decrease) 2.7 2.3 (b) 5.0 Income tax impact — (0.6) (0.6) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes 2.7 1.7 4.4 Net current period other comprehensive income (loss) (270.4) 1.7 (268.7) Balance, September 30, 2022 $ (393.1) $ (60.6) $ (453.7) For the Nine Months Ended October 1, 2021: Balance, December 31, 2020 $ (54.0) $ (87.1) $ (141.1) Other comprehensive income (loss) before reclassifications, net of income taxes (53.8) — (53.8) Amounts reclassified from accumulated other comprehensive income (loss): Increase (decrease) — 3.7 (b) 3.7 Income tax impact — (0.9) (0.9) Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes — 2.8 2.8 Net current period other comprehensive income (loss) (53.8) 2.8 (51.0) Balance, October 1, 2021 $ (107.8) $ (84.3) $ (192.1) (a) Includes balances relating to defined benefit plans, supplemental executive retirement plans, and other postretirement employee benefit plans. (b) This component of AOCI is included in the computation of net periodic pension cost (refer to Note 12 in our most recently filed Form 10-K for additional details).
Schedule of Accounts Receivable, Allowance for Credit Loss	The following is a roll forward of the aggregated allowance for credit losses related to our trade accounts receivables as of September 30, 2022 ($ in millions): Balance, December 31, 2021 $ 39.7 Provision 10.9 Write-offs (7.7) Foreign currency exchange and other (1.4) Balance, September 30, 2022 $ 41.5

ACQUISITIONS AND DIVESTITURES (

ACQUISITIONS AND DIVESTITURES (Tables)	9 Months Ended
ACQUISITIONS AND DIVESTITURES (Tables)	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the estimated fair value of the assets acquired and liabilities assumed from ServiceChannel and Provation as of September 30, 2022 ($ in millions): Provation ServiceChannel Total Accounts receivable $ 41.6 $ 10.1 $ 51.7 Goodwill 976.7 867.6 1,844.3 Other intangible assets, primarily customer relationships, technology, database, and trade names 586.5 342.9 929.4 Deferred revenue, current (50.2) (1.7) (51.9) Deferred tax liabilities (119.4) (41.9) (161.3) Other assets and liabilities, net (30.5) (10.7) (41.2) Net cash consideration $ 1,404.7 $ 1,166.3 $ 2,571.0

GOODWILL (Tables)

GOODWILL (Tables)	9 Months Ended
GOODWILL (Tables)	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following is a roll forward of our carrying value of goodwill by segment ($ in millions): Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Total Goodwill Balance, December 31, 2021 $ 4,126.0 $ 1,840.0 $ 3,186.0 $ 9,152.0 Measurement period adjustments for 2021 acquisitions (5.9) — 8.4 2.5 Attributable to 2022 acquisitions and divestitures — 0.7 (2.6) (1.9) Foreign currency translation and other (79.1) (57.7) (38.3) (175.1) Balance, September 30, 2022 $ 4,041.0 $ 1,783.0 $ 3,153.5 $ 8,977.5

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Liabilities Measured on Recurring Basis	Below is a summary of financial liabilities that are measured at fair value on a recurring basis ($ in millions): Quoted Prices Significant Other Significant Total September 30, 2022 Deferred compensation liabilities $ — $ 29.7 $ — $ 29.7 December 31, 2021 Deferred compensation liabilities — 36.0 — 36.0
Schedule of Carrying Amounts and Fair Values of Financial Instruments	The carrying amount and fair value of financial instruments are as follows ($ in millions): September 30, 2022 December 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Current portion of long-term debt $ 999.9 $ 1,000.0 $ 2,151.7 $ 2,158.3 Long-term debt, net of current maturities 2,559.0 2,381.0 1,807.3 1,978.9

FINANCING AND CAPITAL (Tables)

FINANCING AND CAPITAL (Tables)	9 Months Ended
FINANCING AND CAPITAL (Tables)	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Debt	The carrying value of the components of our long-term debt were as follows ($ in millions): September 30, 2022 December 31, 2021 U.S. dollar-denominated commercial paper $ 747.3 $ 364.9 Delayed-Draw Term Loan due 2022 999.9 999.7 Yen Term Loan due 2025 99.5 — Euro Term Loan due 2025 269.0 — 3.15% senior unsecured notes due 2026 895.9 895.1 4.30% senior unsecured notes due 2046 547.3 547.3 0.875% senior convertible notes due 2022 — 1,152.0 Long-term debt 3,558.9 3,959.0 Less: current portion of long-term debt 999.9 2,151.7 Long-term debt, net of current maturities $ 2,559.0 $ 1,807.3
Schedule of Outstanding Paper Programs	The details of our outstanding Commercial Paper Programs as of September 30, 2022 were as follows ($ in millions): Carrying value Annual effective rate Weighted average remaining maturity (in days) U.S. dollar-denominated commercial paper $ 747.3 3.19 % 29

SALES (Tables)

SALES (Tables)	9 Months Ended
SALES (Tables)	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Contract Liabilities	Our contract liabilities consisted of the following ($ in millions): September 30, 2022 December 31, 2021 Deferred revenue - current $ 472.2 $ 457.6 Deferred revenue - noncurrent 35.2 33.8 Total contract liabilities $ 507.4 $ 491.4
Schedule of Remaining Performance Obligations	The aggregate remaining performance obligations attributable to each of our segments is as follows ($ in millions): September 30, 2022 Intelligent Operating Solutions $ 584.2 Precision Technologies 50.4 Advanced Healthcare Solutions 68.5 Total remaining performance obligations $ 703.1
Schedule of Disaggregation of Revenue	Disaggregation of revenue for the three month period ended September 30, 2022 is presented as follows ($ in millions): Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Sales: Sales of products and software $ 1,227.7 $ 519.2 $ 467.3 $ 241.2 Sales of services 228.3 94.5 56.4 77.4 Total $ 1,456.0 $ 613.7 $ 523.7 $ 318.6 Geographic: United States $ 799.0 $ 342.0 $ 267.8 $ 189.2 China 186.0 56.6 102.6 26.8 All other (each country individually less than 5% of total sales) 471.0 215.1 153.3 102.6 Total $ 1,456.0 $ 613.7 $ 523.7 $ 318.6 End markets: (a) Direct sales: Healthcare $ 354.1 $ 11.1 $ 42.1 $ 300.9 Industrial & Manufacturing 334.5 217.6 111.3 5.6 Utilities & Power 93.1 45.5 47.6 — Government 122.7 65.5 48.7 8.5 Communications, Electronics & Semiconductor 111.3 24.5 86.4 0.4 Aerospace & Defense 66.9 0.1 66.8 — Oil & Gas 66.4 65.3 1.1 — Retail & Consumer 83.9 61.7 22.2 — Other 166.3 91.2 75.1 — Total direct sales 1,399.2 582.5 501.3 315.4 Distributors 56.8 31.2 22.4 3.2 Total $ 1,456.0 $ 613.7 $ 523.7 $ 318.6 (a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer. Disaggregation of revenue for the three month period ended October 1, 2021 is presented as follows ($ in millions): Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Sales: Sales of products and software $ 1,107.1 $ 464.2 $ 401.0 $ 241.9 Sales of services 193.9 72.7 54.7 66.5 Total $ 1,301.0 $ 536.9 $ 455.7 $ 308.4 Geographic: United States $ 685.2 $ 285.3 $ 234.6 $ 165.3 China 154.8 48.8 75.8 30.2 All other (each country individually less than 5% of total sales) 461.0 202.8 145.3 112.9 Total $ 1,301.0 $ 536.9 $ 455.7 $ 308.4 End markets: (a) Direct sales: Healthcare $ 327.6 $ 10.5 $ 30.7 $ 286.4 Industrial & Manufacturing 313.5 204.4 103.2 5.9 Utilities & Power 97.3 55.3 42.0 — Government 100.1 54.6 33.4 12.1 Communications, Electronics & Semiconductor 103.4 30.6 72.3 0.5 Aerospace & Defense 60.6 — 60.6 — Oil & Gas 64.6 62.4 2.2 — Retail & Consumer 53.6 33.0 20.6 — Other 117.7 56.5 61.1 0.1 Total direct sales 1,238.4 507.3 426.1 305.0 Distributors 62.6 29.6 29.6 3.4 Total $ 1,301.0 $ 536.9 $ 455.7 $ 308.4 (a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer. Disaggregation of revenue for the nine month period ended September 30, 2022 is presented as follows ($ in millions): Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Sales: Sales of products and software $ 3,609.8 $ 1,553.9 $ 1,322.6 $ 733.3 Sales of services 686.0 277.5 162.6 245.9 Total $ 4,295.8 $ 1,831.4 $ 1,485.2 $ 979.2 Geographic: United States $ 2,317.9 $ 1,005.0 $ 751.4 $ 561.5 China 514.1 160.6 273.5 80.0 All other (each country individually less than 5% of total sales) 1,463.8 665.8 460.3 337.7 Total $ 4,295.8 $ 1,831.4 $ 1,485.2 $ 979.2 End markets: (a) Direct sales: Healthcare $ 1,077.2 $ 34.6 $ 120.5 $ 922.1 Industrial & Manufacturing 998.3 656.1 322.7 19.5 Utilities & Power 273.4 136.4 137.0 — Government 338.5 177.6 134.8 26.1 Communications, Electronics & Semiconductor 301.2 74.6 225.2 1.4 Aerospace & Defense 187.0 0.4 186.6 — Oil & Gas 199.8 193.4 6.4 — Retail & Consumer 249.5 186.0 63.5 — Other 478.7 268.8 209.8 0.1 Total direct sales 4,103.6 1,727.9 1,406.5 969.2 Distributors 192.2 103.5 78.7 10.0 Total $ 4,295.8 $ 1,831.4 $ 1,485.2 $ 979.2 (a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer. Disaggregation of revenue for the nine month period ended October 1, 2021 is presented as follows ($ in millions): Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Sales: Sales of products and software $ 3,320.3 $ 1,395.6 $ 1,211.6 $ 713.1 Sales of services 559.6 194.0 163.4 202.2 Total $ 3,879.9 $ 1,589.6 $ 1,375 $ 915.3 Geographic: United States $ 1,977.6 $ 810.2 $ 690.0 $ 477.4 China 482.6 162.0 234.3 86.3 All other (each country individually less than 5% of total sales) 1,419.7 617.4 450.7 351.6 Total $ 3,879.9 $ 1,589.6 $ 1,375.0 $ 915.3 End markets: (a) Direct sales: Healthcare $ 983.0 $ 28.3 $ 99.6 $ 855.1 Industrial & Manufacturing 927.9 601.6 308.6 17.7 Utilities & Power 290.0 166.8 123.2 — Government 287.0 150.7 105.7 30.6 Communications, Electronics & Semiconductor 288.8 90.9 196.2 1.7 Aerospace & Defense 181.7 — 181.7 — Oil & Gas 194.6 186.9 7.7 — Retail & Consumer 143.7 75.2 68.5 — Other 379.9 184.3 195.5 0.1 Total direct sales 3,676.6 1,484.7 1,286.7 905.2 Distributors 203.3 104.9 88.3 10.1 Total $ 3,879.9 $ 1,589.6 $ 1,375.0 $ 915.3 (a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
STOCK-BASED COMPENSATION (Tables)	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Costs	The following summarizes the components of our stock-based compensation expense under the Stock Plan ($ in millions): Three Months Ended Nine Months Ended September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 Stock Awards: Pretax compensation expense $ 14.3 $ 11.3 $ 43.0 $ 34.0 Income tax benefit (2.6) (2.1) (7.3) (5.9) Stock Award expense, net of income taxes 11.7 9.2 35.7 28.1 Stock options: Pretax compensation expense 8.6 7.1 24.9 21.2 Income tax benefit (1.4) (1.3) (3.8) (3.8) Stock option expense, net of income taxes 7.2 5.8 21.1 17.4 Total stock-based compensation: Pretax compensation expense 22.9 18.4 67.9 55.2 Income tax benefit (4.0) (3.4) (11.1) (9.7) Total stock-based compensation expense, net of income taxes $ 18.9 $ 15.0 $ 56.8 $ 45.5
Schedule of Future Compensation	Future compensation amounts will be adjusted for any changes in estimated forfeitures ($ in millions): Stock Awards $ 106.6 Stock options 52.7 Total unrecognized compensation cost $ 159.3

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Accrued Warranty Liability	The following is a roll forward of our accrued warranty liability ($ in millions): Balance, December 31, 2021 $ 25.2 Accruals for warranties issued during the period 12.3 Settlements made (14.1) Effect of foreign currency translation and other (0.4) Balance, September 30, 2022 $ 23.0

NET EARNINGS PER SHARE (Tables)

NET EARNINGS PER SHARE (Tables)	9 Months Ended
NET EARNINGS PER SHARE (Tables)	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share	Information related to the calculation of net earnings per share of common stock is summarized as follows ($ and shares in millions, except per share amounts): Three Months Ended Nine Months Ended September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 Numerator Net earnings from continuing operations $ 189.9 $ 152.6 $ 528.0 $ 446.3 Mandatory convertible preferred stock cumulative dividends — — — (34.5) Convertible note interest add-back (if converted method) — — 1.8 — Diluted Net Earnings from Continuing Operations $ 189.9 $ 152.6 $ 529.8 $ 411.8 Denominator Weighted average common shares outstanding used in basic earnings per share 355.2 358.9 357.3 345.6 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive Stock Awards 2.7 3.3 2.6 3.2 Conversion of convertible notes (if converted method) — — 2.1 — Weighted average common shares outstanding used in diluted earnings per share 357.9 362.2 362.0 348.8 Net earnings from continuing operations per common share - Basic $ 0.53 $ 0.42 $ 1.48 $ 1.19 Net earnings from continuing operations per common share - Diluted $ 0.53 $ 0.42 $ 1.46 $ 1.18
Schedule of Dividends Declared	We declared and paid cash dividends per common share for the periods as presented below. We declared and paid the MCPS dividend in the first quarter of 2021, and declared and paid the final dividend in the second quarter of 2021. Dividend Per Amount Dividend per MCPS Amount 2022: First quarter $ 0.07 $ 25.1 $ — $ — Second quarter 0.07 24.9 — — Third quarter 0.07 24.8 — — Total $ 0.21 $ 74.8 $ — $ — 2021: First quarter $ 0.07 $ 23.7 $ 12.5 $ 17.3 Second quarter 0.07 23.7 12.5 17.2 Third quarter 0.07 25.2 — — Total $ 0.21 $ 72.6 $ 25.0 $ 34.5 * The sum of the components of total dividends paid may not equal the total amount due to rounding.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
SEGMENT INFORMATION (Tables)	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	Our segment results are as follows ($ in millions): Three Months Ended Nine Months Ended September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 Sales: Intelligent Operating Solutions $ 613.7 $ 536.9 $ 1,831.4 $ 1,589.6 Precision Technologies 523.7 455.7 1,485.2 1,375.0 Advanced Healthcare Solutions 318.6 308.4 979.2 915.3 Total $ 1,456.0 $ 1,301.0 $ 4,295.8 $ 3,879.9 Operating Profit: Intelligent Operating Solutions $ 132.1 $ 91.5 $ 369.0 $ 314.9 Precision Technologies 131.8 101.1 348.5 301.1 Advanced Healthcare Solutions 17.3 34.4 73.4 75.8 Other (28.2) (24.7) (77.1) (80.6) Russia exit and wind down costs (1.1) — (17.3) — Total Operating Profit 251.9 202.3 696.5 611.2 Interest expense, net (26.4) (25.1) (66.2) (78.0) Loss on extinguishment of debt — — — (104.9) Gain on investment in Vontier Corporation — — — 57.0 Gain on litigation resolution — — — 26.0 Other non-operating expense, net (8.0) (1.6) (13.8) (9.5) Earnings from continuing operations before income taxes $ 217.5 $ 175.6 $ 616.5 $ 501.8

BUSINESS OVERVIEW - Narrative (

BUSINESS OVERVIEW - Narrative (Details) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 01, 2022 USD ($)	Sep. 30, 2022 USD ($) country	Oct. 01, 2021 USD ($)	Sep. 30, 2022 USD ($) country	Oct. 01, 2021 USD ($)	Dec. 31, 2021 USD ($)	Jul. 01, 2022 USD ($)	Jul. 01, 2022 JPY (¥)	Jul. 01, 2022 EUR (€)	Apr. 01, 2022 USD ($)	Jul. 02, 2021 USD ($)	Apr. 02, 2021 USD ($)	Jan. 19, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Feb. 22, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of countries in which entity operates (more than) \| country		50		50
Revenue		$ 1,456	$ 1,301	$ 4,295.8	$ 3,879.9
Principal amount													$ 1,100
Russia exit and wind down costs		1.1	0	17.3	0
Total expected cost				18.4
After-tax foreign currency transaction gains from foreign currency translation		14.6		18.3
Stockholders' equity, including portion attributable to noncontrolling interest		9,395.7		9,395.7		$ 9,517
Revenue Benchmark \| Geographic Concentration Risk \| Russia and Ukraine
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk (as a percent)						1%
Assets, Total \| Geographic Concentration Risk \| Russia and Ukraine
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk (as a percent)						0.20%
Cumulative Effect, Period of Adoption, Adjustment \| Accounting Standards Update 2021-08
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue			1.5		1.5
Additional Paid-In Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity, including portion attributable to noncontrolling interest		3,677.4	3,624.3	3,677.4	3,624.3	$ 3,670	$ 3,651.2			$ 3,619.1	$ 3,602.1	$ 3,563.8		$ 3,554.5
Additional Paid-In Capital \| Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity, including portion attributable to noncontrolling interest						(65.7)
Additional Paid-In Capital \| Cumulative Effect, Period of Adoption, Adjustment \| Accounting Standards Update 2020-06 Cumulative Effect, Period of Adoption
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity, including portion attributable to noncontrolling interest	$ 65.7
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity, including portion attributable to noncontrolling interest		$ 6,539.6	$ 5,883.7	$ 6,539.6	$ 5,883.7	6,023.6	$ 6,374.5			$ 6,226.4	$ 5,756.6	$ 5,616.6		$ 5,547.4
Retained Earnings \| Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity, including portion attributable to noncontrolling interest						$ 62.8
Retained Earnings \| Cumulative Effect, Period of Adoption, Adjustment \| Accounting Standards Update 2020-06 Cumulative Effect, Period of Adoption
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity, including portion attributable to noncontrolling interest	$ 62.8
Yen Term Loan
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Principal amount \| ¥								¥ 14,400,000,000
Euro Term Loan
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Principal amount \| €									€ 275,000,000
0.875% senior convertible notes due 2022 \| Convertible Debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate, stated percentage	0.875%	0.875%	0.875%	0.875%	0.875%							0.875%			0.875%
0.875% senior convertible notes due 2022 \| Convertible Debt \| Cumulative Effect, Period of Adoption, Adjustment \| Accounting Standards Update 2020-06 Cumulative Effect, Period of Adoption
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt instrument, increase (decrease), net	$ 3.7
Vontier
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Investment balance (in shares) \| shares													33.5
Vontier
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Principal amount													$ 1,100

BUSINESS OVERVIEW - Accumulated

BUSINESS OVERVIEW - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jul. 01, 2022	Apr. 01, 2022	Oct. 01, 2021	Jul. 02, 2021	Apr. 02, 2021	Sep. 30, 2022	Oct. 01, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			$ 9,517				$ 9,517
Other comprehensive income (loss) before reclassifications, net of income taxes	$ (112.4)			$ (35.7)			(273.1)	$ (53.8)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)	1.2			1.2			5	3.7
Income tax impact	(0.4)			(0.3)			(0.6)	(0.9)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	0.8			0.9			4.4	2.8
Total other comprehensive income (loss), net of income taxes	(111.6)			(34.8)			(268.7)	(51)
Ending balance	9,395.7						9,395.7
Foreign currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(280.7)		(122.7)	(72.1)		$ (54)	(122.7)	(54)
Other comprehensive income (loss) before reclassifications, net of income taxes	(112.4)			(35.7)			(273.1)	(53.8)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)	0			0			2.7	0
Income tax impact	0			0			0	0
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	0			0			2.7	0
Total other comprehensive income (loss), net of income taxes	(112.4)			(35.7)			(270.4)	(53.8)
Ending balance	(393.1)	$ (280.7)		(107.8)	$ (72.1)		(393.1)	(107.8)
Pension adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(61.4)		(62.3)	(85.2)		(87.1)	(62.3)	(87.1)
Other comprehensive income (loss) before reclassifications, net of income taxes	0			0			0	0
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)	1.2			1.2			2.3	3.7
Income tax impact	(0.4)			(0.3)			(0.6)	(0.9)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	0.8			0.9			1.7	2.8
Total other comprehensive income (loss), net of income taxes	0.8			0.9			1.7	2.8
Ending balance	(60.6)	(61.4)		(84.3)	(85.2)		(60.6)	(84.3)
Accumulated Other Comprehensive Loss
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(342.1)	(223.9)	(185)	(157.3)	(174.8)	(141.1)	(185)	(141.1)
Amounts reclassified from accumulated other comprehensive income (loss):
Total other comprehensive income (loss), net of income taxes	(111.6)	(118.2)	(38.9)	(34.8)	17.5	(33.7)
Ending balance	$ (453.7)	$ (342.1)	$ (223.9)	$ (192.1)	$ (157.3)	$ (174.8)	$ (453.7)	$ (192.1)

BUSINESS OVERVIEW - Allowance f

BUSINESS OVERVIEW - Allowance for Credit Losses Rollforward (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 39.7
Provision	10.9
Write-offs	(7.7)
Foreign currency exchange and other	(1.4)
Ending balance	$ 41.5

ACQUISITIONS AND DIVESTITURES -

ACQUISITIONS AND DIVESTITURES - Narrative (Details) - USD ($) $ in Millions			3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 27, 2021	Aug. 24, 2021	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill			$ 8,977.5	$ 8,977.5	$ 9,152
Therapy Physics Product Line \| Business Line Concentration Risk \| Revenue Benchmark
Business Acquisition [Line Items]
Concentration risk (as a percent)					1%
Therapy Physics Product Line \| Business Line Concentration Risk \| Assets, Total
Business Acquisition [Line Items]
Concentration risk (as a percent)					1%
Therapy Physics Product Line \| Disposal Group, Disposed of by Sale, Not Discontinued Operations
Business Acquisition [Line Items]
Consideration from sale of business			9.6	9.6
Pre-tax realized gain on sale			2.3	2.3
Provation
Business Acquisition [Line Items]
Total purchase price	$ 1,400
Goodwill	$ 977		976.7	976.7
Revenue of prior fiscal year						$ 90
ServiceChannel
Business Acquisition [Line Items]
Total purchase price		$ 1,200
Goodwill		868	867.6	867.6
Revenue of prior fiscal year						$ 70
Deferred compensation consideration		$ 28
Provation and Service Channel Acquisition
Business Acquisition [Line Items]
Goodwill			$ 1,844.3	1,844.3
Revenue of acquiree since acquisition date				198
Operating loss of acquiree since acquisition date				38
Amortization of intangibles and integration and transaction costs attributable to acquiree				57.9
Transaction-related costs				$ 18.8

ACQUISITIONS AND DIVESTITURES_2

ACQUISITIONS AND DIVESTITURES - Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021	Dec. 27, 2021	Aug. 24, 2021
Business Acquisition [Line Items]
Goodwill	$ 8,977.5	$ 9,152
Provation
Business Acquisition [Line Items]
Accounts receivable	41.6
Goodwill	976.7		$ 977
Other intangible assets, primarily customer relationships, technology, database, and trade names	586.5
Deferred revenue, current	(50.2)
Deferred tax liabilities	(119.4)
Other assets and liabilities, net	(30.5)
Net cash consideration	1,404.7
ServiceChannel
Business Acquisition [Line Items]
Accounts receivable	10.1
Goodwill	867.6			$ 868
Other intangible assets, primarily customer relationships, technology, database, and trade names	342.9
Deferred revenue, current	(1.7)
Deferred tax liabilities	(41.9)
Other assets and liabilities, net	(10.7)
Net cash consideration	1,166.3
Provation and Service Channel Acquisition
Business Acquisition [Line Items]
Accounts receivable	51.7
Goodwill	1,844.3
Other intangible assets, primarily customer relationships, technology, database, and trade names	929.4
Deferred revenue, current	(51.9)
Deferred tax liabilities	(161.3)
Other assets and liabilities, net	(41.2)
Net cash consideration	$ 2,571

GOODWILL - Rollforward of Goodw

GOODWILL - Rollforward of Goodwill (Details) $ in Millions	9 Months Ended
GOODWILL - Rollforward of Goodwill (Details) $ in Millions	Sep. 30, 2022 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 9,152
Measurement period adjustments for 2021 acquisitions	2.5
Attributable to 2022 acquisitions and divestitures	(1.9)
Foreign currency translation and other	(175.1)
Ending balance	8,977.5
Intelligent Operating Solutions
Goodwill [Roll Forward]
Beginning balance	4,126
Measurement period adjustments for 2021 acquisitions	(5.9)
Attributable to 2022 acquisitions and divestitures	0
Foreign currency translation and other	(79.1)
Ending balance	4,041
Precision Technologies
Goodwill [Roll Forward]
Beginning balance	1,840
Measurement period adjustments for 2021 acquisitions	0
Attributable to 2022 acquisitions and divestitures	0.7
Foreign currency translation and other	(57.7)
Ending balance	1,783
Advanced Healthcare Solutions
Goodwill [Roll Forward]
Beginning balance	3,186
Measurement period adjustments for 2021 acquisitions	8.4
Attributable to 2022 acquisitions and divestitures	(2.6)
Foreign currency translation and other	(38.3)
Ending balance	$ 3,153.5

FAIR VALUE MEASUREMENTS - Fair

FAIR VALUE MEASUREMENTS - Fair Value Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loss on impairment of equity investment	$ 8.1	$ 8.1
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation liabilities	29.7	29.7	$ 36
Fair Value, Measurements, Recurring \| Quoted Prices in Active Market (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation liabilities	0	0	0
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation liabilities	29.7	29.7	36
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation liabilities	$ 0	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Carry

FAIR VALUE MEASUREMENTS - Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current portion of long-term debt, carrying amount	$ 999.9	$ 2,151.7
Long-term debt, net of current maturities, carrying value	2,559	1,807.3
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current portion of long-term debt, carrying amount	999.9	2,151.7
Current portion of long-term debt, fair value	1,000	2,158.3
Long-term debt, net of current maturities, carrying value	2,559	1,807.3
Long-term debt, net of current maturities, fair value	$ 2,381	$ 1,978.9

FINANCING AND CAPITAL - Compone

FINANCING AND CAPITAL - Components of Debt (Details) - USD ($) $ in Millions	Sep. 30, 2022	Jan. 01, 2022	Dec. 31, 2021	Oct. 01, 2021	Apr. 02, 2021	Feb. 22, 2019
Debt Instrument [Line Items]
Long-term debt	$ 3,558.9		$ 3,959
Less: current portion of long-term debt	999.9		2,151.7
Long-term debt, net of current maturities	2,559		1,807.3
Delayed-Draw Term Loan due 2022
Debt Instrument [Line Items]
Long-term debt	999.9		999.7
Yen Term Loan due 2025
Debt Instrument [Line Items]
Long-term debt	99.5		0
Euro Term Loan due 2025
Debt Instrument [Line Items]
Long-term debt	269		0
Commercial Paper \| U.S. dollar-denominated commercial paper
Debt Instrument [Line Items]
Long-term debt	747.3		364.9
Convertible and Registered Notes \| 3.15% senior unsecured notes due 2026
Debt Instrument [Line Items]
Long-term debt	$ 895.9		895.1
Interest rate, stated percentage	3.15%
Convertible and Registered Notes \| 4.30% senior unsecured notes due 2046
Debt Instrument [Line Items]
Long-term debt	$ 547.3		547.3
Interest rate, stated percentage	4.30%
Convertible Debt \| 0.875% senior convertible notes due 2022
Debt Instrument [Line Items]
Long-term debt	$ 0		$ 1,152			$ 1,300
Interest rate, stated percentage	0.875%	0.875%		0.875%	0.875%	0.875%

FINANCING AND CAPITAL - Narrati

FINANCING AND CAPITAL - Narrative (Details) shares in Millions

3 Months Ended

9 Months Ended

Oct. 18, 2022 USD ($) extension

Jun. 28, 2022 USD ($)

Jun. 21, 2022

Jun. 17, 2022 USD ($)

Feb. 15, 2022 USD ($)

Feb. 09, 2021 USD ($)

Feb. 22, 2019 USD ($)

Sep. 30, 2022 USD ($)

Oct. 01, 2021 USD ($)

Apr. 02, 2021 USD ($)

Sep. 30, 2022 USD ($)

Oct. 01, 2021 USD ($)

Jul. 01, 2022 JPY (¥)

Jul. 01, 2022 EUR (€)

Jan. 01, 2022

Dec. 31, 2021 USD ($)

Jan. 19, 2021 USD ($) shares

Debt Instrument [Line Items]

Debt discounts, premiums and issuance costs

$ 8,100,000

$ 13,000,000

Principal amount

$ 1,100,000,000

Carrying value

3,558,900,000

3,959,000,000

Loss on extinguishment of debt

$ 0

$ 104,900,000

Repayments of convertible debt

1,156,500,000

Interest expense

26,400,000

$ 25,100,000

$ 66,200,000

78,000,000

Vontier

Debt Instrument [Line Items]

Investment balance (in shares) | shares

33.5

Gain on investment in Vontier Corporation

$ 57,000,000

Yen Term Loan

Debt Instrument [Line Items]

Debt term

3 years

Principal amount | ¥

¥ 14,400,000,000

Net proceeds yielded

$ 107,000,000

Yen Term Loan | Tokyo Term Risk Free Rate

Debt Instrument [Line Items]

Basis spread on variable interest rate

0.65%

Euro Term Loan

Debt Instrument [Line Items]

Debt term

3 years

Principal amount | €

€ 275,000,000

Net proceeds yielded

$ 290,000,000

Euro Term Loan | Euro Interbank Offered Rate

Debt Instrument [Line Items]

Basis spread on variable interest rate

0.55%

Revolving Credit Facility

Debt Instrument [Line Items]

Debt term

5 years

Maximum borrowing capacity

2,000,000,000

$ 2,000,000,000

Outstanding borrowings

$ 0

Revolving Credit Facility | Subsequent Event

Debt Instrument [Line Items]

Maximum borrowing capacity

$ 1,000,000,000

Number of extension options | extension

Extension period

1 year

Increase or decrease in interest rate (as a percent)

0.04%

Increase or decrease in facility fee (as a percent)

0.01%

Maximum impact on increase or decrease in interest rate (as a percent)

0.05%

Maximum consolidated net leverage ratio of debt to consolidated EBITDA

3.5

Maximum consolidated net leverage ratio increase for four consecutive full quarters

Debt covenant, purchase price of business

$ 250,000,000

Revolving Credit Facility | Maximum | Subsequent Event

Debt Instrument [Line Items]

Annual facility fee (as a percent)

0.15%

Revolving Credit Facility | Minimum | Subsequent Event

Debt Instrument [Line Items]

Annual facility fee (as a percent)

0.065%

Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Subsequent Event | Debt Instrument, Interest Rate, Option One

Debt Instrument [Line Items]

Basis spread on variable interest rate

0.10%

Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Subsequent Event | Debt Instrument, Interest Rate, Option Two

Debt Instrument [Line Items]

Basis spread on variable interest rate

Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Maximum | Subsequent Event | Debt Instrument, Interest Rate, Option One

Debt Instrument [Line Items]

Basis spread on variable interest rate

1.10%

Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Maximum | Subsequent Event | Debt Instrument, Interest Rate, Option Two

Debt Instrument [Line Items]

Basis spread on variable interest rate

0.10%

Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum | Subsequent Event | Debt Instrument, Interest Rate, Option One

Debt Instrument [Line Items]

Basis spread on variable interest rate

0.685%

Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum | Subsequent Event | Debt Instrument, Interest Rate, Option Two

Debt Instrument [Line Items]

Basis spread on variable interest rate

Revolving Credit Facility | Fed Funds Effective Rate Overnight Index Swap Rate | Subsequent Event | Debt Instrument, Interest Rate, Option Two

Debt Instrument [Line Items]

Basis spread on variable interest rate

0.50%

Line of Credit

Debt Instrument [Line Items]

Loss on extinguishment of debt

94,400,000

Additional Paid-In Capital

Debt Instrument [Line Items]

Early extinguishment of 0.875% convertible senior notes due 2022

$ 11,600,000

$ (11,600,000)

Convertible Debt

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 10,500,000

Interest expense

$ 2,100,000

Convertible Debt | 0.875% senior convertible notes due 2022

Debt Instrument [Line Items]

Proceeds from the issuance of convertible notes

$ 1,400,000,000

Interest rate, stated percentage

0.875%

Carrying value

$ 1,300,000,000

$ 0

1,152,000,000

Discount at issuance

$ 102,200,000

Effective interest rate

3.38%

Debt issuance costs

$ 24,300,000

Debt instrument, repurchased face amount

$ 281,000,000

Repayments of convertible debt

$ 1,200,000,000

Interest expense

$ 11,100,000

$ 34,500,000

Interest expense, debt

2,500,000

1,300,000

7,900,000

Amortization of debt issuance costs

1,500,000

$ 800,000

4,700,000

Amortization of debt discount

$ 7,100,000

$ 21,900,000

Convertible Debt | Senior Unsecured Notes due 2022, Over-Allotment Option

Debt Instrument [Line Items]

Principal amount

$ 187,500,000

Commercial Paper | U.S. dollar-denominated commercial paper

Debt Instrument [Line Items]

Debt term

29 days

Carrying value

$ 747,300,000

$ 364,900,000

Effective interest rate

3.19%

Commercial Paper | U.S. dollar-denominated commercial paper | Maximum

Debt Instrument [Line Items]

Debt term

397 days

Commercial Paper | Euro-denominated commercial paper | Maximum

Debt Instrument [Line Items]

Debt term

183 days

Unsecured Debt | Delayed-Draw Term Loan Due 2023 | Subsequent Event | Unsecured Debt

Debt Instrument [Line Items]

Principal amount

$ 1,000,000,000

Unsecured Debt | Delayed-Draw Term Loan Due 2023 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Subsequent Event | Unsecured Debt

Debt Instrument [Line Items]

Basis spread on variable interest rate

0.825%

Credit spread adjustment (as a percent)

0.10%

SALES - Narrative (Details)

SALES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
SALES - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Capitalized Contract Cost [Line Items]
Contract assets	$ 84	$ 84	$ 71
Net revenue-related contract assets	37	37	$ 27
Contract liabilities, revenue recognized	$ 63	$ 319
Minimum
Capitalized Contract Cost [Line Items]
Useful life	3 years	3 years
Maximum
Capitalized Contract Cost [Line Items]
Useful life	8 years	8 years
Maximum \| Deferred Sales Commissions
Capitalized Contract Cost [Line Items]
Useful life	1 year	1 year

SALES - Contract liabilities (D

SALES - Contract liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Deferred revenue - current	$ 472.2	$ 457.6
Deferred revenue - noncurrent	35.2	33.8
Total contract liabilities	$ 507.4	$ 491.4

SALES - Revenue, Remaining Perf

SALES - Revenue, Remaining Performance Obligation (Details) $ in Millions	Sep. 30, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 703.1
Intelligent Operating Solutions \| Operating Segments
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	584.2
Precision Technologies \| Operating Segments
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	50.4
Advanced Healthcare Solutions \| Operating Segments
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 68.5

SALES - Remaining Performance O

SALES - Remaining Performance Obligation, Expected Timing (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01	Sep. 30, 2022
Period One
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	80%
Remaining performance obligation, expected timing	2 years
Period Two
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	90%
Remaining performance obligation, expected timing	3 years
Period Three
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	100%
Remaining performance obligation, expected timing	4 years

SALES - Disaggregation of Reven

SALES - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Disaggregation of Revenue [Line Items]
Total sales	$ 1,456	$ 1,301	$ 4,295.8	$ 3,879.9
Healthcare
Disaggregation of Revenue [Line Items]
Total sales	354.1	327.6	1,077.2	983
Industrial & Manufacturing
Disaggregation of Revenue [Line Items]
Total sales	334.5	313.5	998.3	927.9
Utilities & Power
Disaggregation of Revenue [Line Items]
Total sales	93.1	97.3	273.4	290
Government
Disaggregation of Revenue [Line Items]
Total sales	122.7	100.1	338.5	287
Communications, Electronics & Semiconductor
Disaggregation of Revenue [Line Items]
Total sales	111.3	103.4	301.2	288.8
Aerospace & Defense
Disaggregation of Revenue [Line Items]
Total sales	66.9	60.6	187	181.7
Oil & Gas
Disaggregation of Revenue [Line Items]
Total sales	66.4	64.6	199.8	194.6
Retail & Consumer
Disaggregation of Revenue [Line Items]
Total sales	83.9	53.6	249.5	143.7
Other
Disaggregation of Revenue [Line Items]
Total sales	166.3	117.7	478.7	379.9
Total direct sales
Disaggregation of Revenue [Line Items]
Total sales	1,399.2	1,238.4	4,103.6	3,676.6
Distributors
Disaggregation of Revenue [Line Items]
Total sales	56.8	62.6	192.2	203.3
Intelligent Operating Solutions \| Healthcare
Disaggregation of Revenue [Line Items]
Total sales			34.6
Intelligent Operating Solutions \| Industrial & Manufacturing
Disaggregation of Revenue [Line Items]
Total sales			656.1
Intelligent Operating Solutions \| Utilities & Power
Disaggregation of Revenue [Line Items]
Total sales			136.4
Intelligent Operating Solutions \| Government
Disaggregation of Revenue [Line Items]
Total sales			177.6
Intelligent Operating Solutions \| Communications, Electronics & Semiconductor
Disaggregation of Revenue [Line Items]
Total sales			74.6
Intelligent Operating Solutions \| Aerospace & Defense
Disaggregation of Revenue [Line Items]
Total sales			0.4
Intelligent Operating Solutions \| Oil & Gas
Disaggregation of Revenue [Line Items]
Total sales			193.4
Intelligent Operating Solutions \| Retail & Consumer
Disaggregation of Revenue [Line Items]
Total sales			186
Intelligent Operating Solutions \| Other
Disaggregation of Revenue [Line Items]
Total sales			268.8
Intelligent Operating Solutions \| Distributors
Disaggregation of Revenue [Line Items]
Total sales			103.5
Precision Technologies \| Healthcare
Disaggregation of Revenue [Line Items]
Total sales			120.5
Precision Technologies \| Industrial & Manufacturing
Disaggregation of Revenue [Line Items]
Total sales			322.7
Precision Technologies \| Utilities & Power
Disaggregation of Revenue [Line Items]
Total sales			137
Precision Technologies \| Government
Disaggregation of Revenue [Line Items]
Total sales			134.8
Precision Technologies \| Communications, Electronics & Semiconductor
Disaggregation of Revenue [Line Items]
Total sales			225.2
Precision Technologies \| Aerospace & Defense
Disaggregation of Revenue [Line Items]
Total sales			186.6
Precision Technologies \| Oil & Gas
Disaggregation of Revenue [Line Items]
Total sales			6.4
Precision Technologies \| Retail & Consumer
Disaggregation of Revenue [Line Items]
Total sales			63.5
Precision Technologies \| Other
Disaggregation of Revenue [Line Items]
Total sales			209.8
Precision Technologies \| Distributors
Disaggregation of Revenue [Line Items]
Total sales			78.7
Advanced Healthcare Solutions \| Healthcare
Disaggregation of Revenue [Line Items]
Total sales			922.1
Advanced Healthcare Solutions \| Industrial & Manufacturing
Disaggregation of Revenue [Line Items]
Total sales			19.5
Advanced Healthcare Solutions \| Utilities & Power
Disaggregation of Revenue [Line Items]
Total sales			0
Advanced Healthcare Solutions \| Government
Disaggregation of Revenue [Line Items]
Total sales			26.1
Advanced Healthcare Solutions \| Communications, Electronics & Semiconductor
Disaggregation of Revenue [Line Items]
Total sales			1.4
Advanced Healthcare Solutions \| Aerospace & Defense
Disaggregation of Revenue [Line Items]
Total sales			0
Advanced Healthcare Solutions \| Oil & Gas
Disaggregation of Revenue [Line Items]
Total sales			0
Advanced Healthcare Solutions \| Retail & Consumer
Disaggregation of Revenue [Line Items]
Total sales			0
Advanced Healthcare Solutions \| Other
Disaggregation of Revenue [Line Items]
Total sales			0.1
Advanced Healthcare Solutions \| Distributors
Disaggregation of Revenue [Line Items]
Total sales			10
Operating Segments \| Intelligent Operating Solutions
Disaggregation of Revenue [Line Items]
Total sales	613.7	536.9	1,831.4	1,589.6
Operating Segments \| Intelligent Operating Solutions \| Healthcare
Disaggregation of Revenue [Line Items]
Total sales	11.1	10.5		28.3
Operating Segments \| Intelligent Operating Solutions \| Industrial & Manufacturing
Disaggregation of Revenue [Line Items]
Total sales	217.6	204.4		601.6
Operating Segments \| Intelligent Operating Solutions \| Utilities & Power
Disaggregation of Revenue [Line Items]
Total sales	45.5	55.3		166.8
Operating Segments \| Intelligent Operating Solutions \| Government
Disaggregation of Revenue [Line Items]
Total sales	65.5	54.6		150.7
Operating Segments \| Intelligent Operating Solutions \| Communications, Electronics & Semiconductor
Disaggregation of Revenue [Line Items]
Total sales	24.5	30.6		90.9
Operating Segments \| Intelligent Operating Solutions \| Aerospace & Defense
Disaggregation of Revenue [Line Items]
Total sales	0.1	0		0
Operating Segments \| Intelligent Operating Solutions \| Oil & Gas
Disaggregation of Revenue [Line Items]
Total sales	65.3	62.4		186.9
Operating Segments \| Intelligent Operating Solutions \| Retail & Consumer
Disaggregation of Revenue [Line Items]
Total sales	61.7	33		75.2
Operating Segments \| Intelligent Operating Solutions \| Other
Disaggregation of Revenue [Line Items]
Total sales	91.2	56.5		184.3
Operating Segments \| Intelligent Operating Solutions \| Total direct sales
Disaggregation of Revenue [Line Items]
Total sales	582.5	507.3	1,727.9	1,484.7
Operating Segments \| Intelligent Operating Solutions \| Distributors
Disaggregation of Revenue [Line Items]
Total sales	31.2	29.6		104.9
Operating Segments \| Precision Technologies
Disaggregation of Revenue [Line Items]
Total sales	523.7	455.7	1,485.2	1,375
Operating Segments \| Precision Technologies \| Healthcare
Disaggregation of Revenue [Line Items]
Total sales	42.1	30.7		99.6
Operating Segments \| Precision Technologies \| Industrial & Manufacturing
Disaggregation of Revenue [Line Items]
Total sales	111.3	103.2		308.6
Operating Segments \| Precision Technologies \| Utilities & Power
Disaggregation of Revenue [Line Items]
Total sales	47.6	42		123.2
Operating Segments \| Precision Technologies \| Government
Disaggregation of Revenue [Line Items]
Total sales	48.7	33.4		105.7
Operating Segments \| Precision Technologies \| Communications, Electronics & Semiconductor
Disaggregation of Revenue [Line Items]
Total sales	86.4	72.3		196.2
Operating Segments \| Precision Technologies \| Aerospace & Defense
Disaggregation of Revenue [Line Items]
Total sales	66.8	60.6		181.7
Operating Segments \| Precision Technologies \| Oil & Gas
Disaggregation of Revenue [Line Items]
Total sales	1.1	2.2		7.7
Operating Segments \| Precision Technologies \| Retail & Consumer
Disaggregation of Revenue [Line Items]
Total sales	22.2	20.6		68.5
Operating Segments \| Precision Technologies \| Other
Disaggregation of Revenue [Line Items]
Total sales	75.1	61.1		195.5
Operating Segments \| Precision Technologies \| Total direct sales
Disaggregation of Revenue [Line Items]
Total sales	501.3	426.1	1,406.5	1,286.7
Operating Segments \| Precision Technologies \| Distributors
Disaggregation of Revenue [Line Items]
Total sales	22.4	29.6		88.3
Operating Segments \| Advanced Healthcare Solutions
Disaggregation of Revenue [Line Items]
Total sales	318.6	308.4	979.2	915.3
Operating Segments \| Advanced Healthcare Solutions \| Healthcare
Disaggregation of Revenue [Line Items]
Total sales	300.9	286.4		855.1
Operating Segments \| Advanced Healthcare Solutions \| Industrial & Manufacturing
Disaggregation of Revenue [Line Items]
Total sales	5.6	5.9		17.7
Operating Segments \| Advanced Healthcare Solutions \| Utilities & Power
Disaggregation of Revenue [Line Items]
Total sales	0	0		0
Operating Segments \| Advanced Healthcare Solutions \| Government
Disaggregation of Revenue [Line Items]
Total sales	8.5	12.1		30.6
Operating Segments \| Advanced Healthcare Solutions \| Communications, Electronics & Semiconductor
Disaggregation of Revenue [Line Items]
Total sales	0.4	0.5		1.7
Operating Segments \| Advanced Healthcare Solutions \| Aerospace & Defense
Disaggregation of Revenue [Line Items]
Total sales	0	0		0
Operating Segments \| Advanced Healthcare Solutions \| Oil & Gas
Disaggregation of Revenue [Line Items]
Total sales	0	0		0
Operating Segments \| Advanced Healthcare Solutions \| Retail & Consumer
Disaggregation of Revenue [Line Items]
Total sales	0	0		0
Operating Segments \| Advanced Healthcare Solutions \| Other
Disaggregation of Revenue [Line Items]
Total sales	0	0.1		0.1
Operating Segments \| Advanced Healthcare Solutions \| Total direct sales
Disaggregation of Revenue [Line Items]
Total sales	315.4	305	969.2	905.2
Operating Segments \| Advanced Healthcare Solutions \| Distributors
Disaggregation of Revenue [Line Items]
Total sales	3.2	3.4		10.1
United States
Disaggregation of Revenue [Line Items]
Total sales	799	685.2	2,317.9	1,977.6
United States \| Operating Segments \| Intelligent Operating Solutions
Disaggregation of Revenue [Line Items]
Total sales	342	285.3	1,005	810.2
United States \| Operating Segments \| Precision Technologies
Disaggregation of Revenue [Line Items]
Total sales	267.8	234.6	751.4	690
United States \| Operating Segments \| Advanced Healthcare Solutions
Disaggregation of Revenue [Line Items]
Total sales	189.2	165.3	561.5	477.4
China
Disaggregation of Revenue [Line Items]
Total sales	186	154.8	514.1	482.6
China \| Operating Segments \| Intelligent Operating Solutions
Disaggregation of Revenue [Line Items]
Total sales	56.6	48.8	160.6	162
China \| Operating Segments \| Precision Technologies
Disaggregation of Revenue [Line Items]
Total sales	102.6	75.8	273.5	234.3
China \| Operating Segments \| Advanced Healthcare Solutions
Disaggregation of Revenue [Line Items]
Total sales	26.8	30.2	80	86.3
All other (each country individually less than 5% of total sales)
Disaggregation of Revenue [Line Items]
Total sales	471	461	1,463.8	1,419.7
All other (each country individually less than 5% of total sales) \| Operating Segments \| Intelligent Operating Solutions
Disaggregation of Revenue [Line Items]
Total sales	215.1	202.8	665.8	617.4
All other (each country individually less than 5% of total sales) \| Operating Segments \| Precision Technologies
Disaggregation of Revenue [Line Items]
Total sales	153.3	145.3	460.3	450.7
All other (each country individually less than 5% of total sales) \| Operating Segments \| Advanced Healthcare Solutions
Disaggregation of Revenue [Line Items]
Total sales	102.6	112.9	337.7	351.6
Sales of products and software
Disaggregation of Revenue [Line Items]
Total sales	1,227.7	1,107.1	3,609.8	3,320.3
Sales of products and software \| Operating Segments \| Intelligent Operating Solutions
Disaggregation of Revenue [Line Items]
Total sales	519.2	464.2	1,553.9	1,395.6
Sales of products and software \| Operating Segments \| Precision Technologies
Disaggregation of Revenue [Line Items]
Total sales	467.3	401	1,322.6	1,211.6
Sales of products and software \| Operating Segments \| Advanced Healthcare Solutions
Disaggregation of Revenue [Line Items]
Total sales	241.2	241.9	733.3	713.1
Sales of services
Disaggregation of Revenue [Line Items]
Total sales	228.3	193.9	686	559.6
Sales of services \| Operating Segments \| Intelligent Operating Solutions
Disaggregation of Revenue [Line Items]
Total sales	94.5	72.7	277.5	194
Sales of services \| Operating Segments \| Precision Technologies
Disaggregation of Revenue [Line Items]
Total sales	56.4	54.7	162.6	163.4
Sales of services \| Operating Segments \| Advanced Healthcare Solutions
Disaggregation of Revenue [Line Items]
Total sales	$ 77.4	$ 66.5	$ 245.9	$ 202.2

INCOME TAXES (Details)

INCOME TAXES (Details)	3 Months Ended		9 Months Ended
INCOME TAXES (Details)	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Income Tax Disclosure [Abstract]
Effective tax rate (as a percent)	12.70%	13.10%	14.40%	11.10%

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) shares in Millions	9 Months Ended
	Sep. 30, 2022 shares
Share-Based Payment Arrangement [Abstract]
Shares of common stock reserved for issuance under the stock plan (in shares)	16
Remaining service period related to the awards	2 years

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	$ 22.9	$ 18.4	$ 67.9	$ 55.2
Income tax benefit	(4)	(3.4)	(11.1)	(9.7)
Total stock-based compensation expense	18.9	15	56.8	45.5
Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	14.3	11.3	43	34
Income tax benefit	(2.6)	(2.1)	(7.3)	(5.9)
Total stock-based compensation expense	11.7	9.2	35.7	28.1
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	8.6	7.1	24.9	21.2
Income tax benefit	(1.4)	(1.3)	(3.8)	(3.8)
Total stock-based compensation expense	$ 7.2	$ 5.8	$ 21.1	$ 17.4

STOCK-BASED COMPENSATION - Unre

STOCK-BASED COMPENSATION - Unrecognized Compensation Cost (Details) $ in Millions	Sep. 30, 2022 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$ 159.3
Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	106.6
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$ 52.7

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Rollforward of Accrued Warranty Liability (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Warranty period - minimum	90 days
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$ 25.2
Accruals for warranties issued during the period	12.3
Settlements made	(14.1)
Effect of foreign currency translation and other	(0.4)
Ending balance	$ 23

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 13	$ 15	$ 42	$ 45
Cash paid for operating leases			38	40
ROU assets obtained in exchange for operating lease obligations			$ 18	$ 24

NET EARNINGS PER SHARE - Narrat

NET EARNINGS PER SHARE - Narrative (Details)		3 Months Ended		9 Months Ended
NET EARNINGS PER SHARE - Narrative (Details)	Jul. 01, 2021 shares	Sep. 30, 2022 USD ($) shares	Oct. 01, 2021 shares	Sep. 30, 2022 USD ($) shares	Oct. 01, 2021 shares	Feb. 17, 2022 shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred stock, dividend rate (as a percent)	5%
Convertible preferred stock, conversion ratio	14.0978
Number of shares authorized to be repurchased (in shares)						20,000,000
Number of shares authorized to be repurchased \| $		$ 14,000,000		$ 14,000,000
Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion of stock, common stock issued (in shares)	19,400,000
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)		7,300,000	200,000	7,300,000	300,000

NET EARNINGS PER SHARE - Earnin

NET EARNINGS PER SHARE - Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Numerator
Net earnings from continuing operations	$ 189.9	$ 152.6	$ 528	$ 446.3
Mandatory convertible preferred stock cumulative dividends	0	0	0	(34.5)
Convertible note interest add-back (if converted method)	0	0	1.8	0
Diluted Net Earnings from Continuing Operations	$ 189.9	$ 152.6	$ 529.8	$ 411.8
Denominator
Weighted average common shares outstanding used in basic earnings per share (in shares)	355.2	358.9	357.3	345.6
Incremental common shares from:
Assumed exercise of dilutive options and vesting of dilutive stock awards (in shares)	2.7	3.3	2.6	3.2
Conversion of convertible notes (if converted method) (in shares)	0	0	2.1	0
Weighted average common shares outstanding used in diluted earnings per share (in shares)	357.9	362.2	362	348.8
Net earnings from continuing operations per common share - Basic (in dollars per share)	$ 0.53	$ 0.42	$ 1.48	$ 1.19
Net earnings from continuing operations per common share - Diluted (in dollars per share)	$ 0.53	$ 0.42	$ 1.46	$ 1.18

NET EARNINGS PER SHARE - Divide

NET EARNINGS PER SHARE - Dividends Declared and Paid (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jul. 01, 2022	Apr. 01, 2022	Oct. 01, 2021	Jul. 02, 2021	Apr. 02, 2021	Sep. 30, 2022	Oct. 01, 2021
Earnings Per Share [Abstract]
Dividend per common share (in dollars per share)	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.21	$ 0.21
Amount, common shares	$ 24.8	$ 24.9	$ 25.1	$ 25.2	$ 23.7	$ 23.7	$ 74.8	$ 72.6
Dividend per MCPS (in dollars per share)	$ 0	$ 0	$ 0	$ 0	$ 12.5	$ 12.5	$ 0	$ 25
Amount, MCPS	$ 0	$ 0	$ 0		$ 17.2	$ 17.3	$ 0	$ 34.5

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	9 Months Ended
SEGMENT INFORMATION - Narrative (Details)	Sep. 30, 2022 segment
Segment Reporting [Abstract]
Number of operating segments	3

SEGMENT INFORMATION - Detailed

SEGMENT INFORMATION - Detailed Segment Data (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Segment Reporting Information [Line Items]
Total sales	$ 1,456	$ 1,301	$ 4,295.8	$ 3,879.9
Total Operating Profit	251.9	202.3	696.5	611.2
Russia exit and wind down costs	(1.1)	0	(17.3)	0
Interest expense, net	(26.4)	(25.1)	(66.2)	(78)
Loss on extinguishment of debt	0	0	0	(104.9)
Gain on investment in Vontier Corporation	0	0	0	57
Gain on litigation resolution	0	0	0	26
Other non-operating expense, net	(8)	(1.6)	(13.8)	(9.5)
Earnings from continuing operations before income taxes	217.5	175.6	616.5	501.8
Operating Segments \| Intelligent Operating Solutions
Segment Reporting Information [Line Items]
Total sales	613.7	536.9	1,831.4	1,589.6
Total Operating Profit	132.1	91.5	369	314.9
Operating Segments \| Precision Technologies
Segment Reporting Information [Line Items]
Total sales	523.7	455.7	1,485.2	1,375
Total Operating Profit	131.8	101.1	348.5	301.1
Operating Segments \| Advanced Healthcare Solutions
Segment Reporting Information [Line Items]
Total sales	318.6	308.4	979.2	915.3
Total Operating Profit	17.3	34.4	73.4	75.8
Operating Segments \| Russia exit and wind down costs
Segment Reporting Information [Line Items]
Total Operating Profit	(1.1)	0	(17.3)	0
Other
Segment Reporting Information [Line Items]
Total Operating Profit	$ (28.2)	$ (24.7)	$ (77.1)	$ (80.6)